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Endometriosis is a chronic, debilitating inflammatory disease. It is characterized by ectopic 
formation of estrogen-sensitive endometrial glands and stroma mostly on the surface of the 
ovaries, fallopian tubes, and pelvic cavity. Major complaints of endometriosis patients are pelvic 
pain, dysmenorrhea and infertility, which decrease the quality of life of these women. Non-
steroidal anti-inflammatory medications and oral contraceptives are the first line of treatment to 
alleviate the symptoms and regress the lesions. The diagnosis of the disease is a hurdle; there are 
no specific markers for endometriosis, and the only approach to confirm the disease is by 
laparoscopy. The reason for limited treatment and diagnosis options is the lack of complete 
understanding of endometriosis pathophysiology. Retrograde menstruation is one of the most 
accepted theories, however, considering that retrograde menstruation is a normal process in most 
women of reproductive age, the causes of the establishment and survival of endometriotic tissue 
in these patients is not clear. Several studies suggested that microRNAs may play a significant role 
in endometriosis development. MicroRNAs are small non-coding RNAs that stimulate or inhibit 
the transcription of specific gene targets. Mis-expression of microRNAs has been established in 
endometriosis and is linked to its cellular phenotypes. miRNA-451 (now referred to as miR-451a), 
is one of the most differential expressed miRNAs in endometriotic lesions from women with 
endometriosis.  It is well-established that miR-451a modulates cell survival, but its potential role 
in endometriosis is poorly understood.  We have previously demonstrated that miR-451a regulates 
expression of factors essential for endometriotic lesion survival.  The objective of this project was 
to further explore the mechanisms and mediators through which miR-451a may modulate 
endometriotic lesion and cell survival.  To accomplish our goal, we over-expressed miR-451a in 
the immortalized endometriotic epithelial 12Z cell line and screened differentially expressed 
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proteins by 2-DiGE analysis. As a result, RPLP1, Ribosomal Protein Large P1, was found to be 
decreased in 12Z cells which over-expressed miR-451a. RPLP1 is a component of 60S ribosomal 
subunit which aids in the translation elongation process and is speculated to drive cell proliferation. 
Thus, the overall hypothesis of this research project is that RPLP1is a target of miR-451a and its 
expression is related to the proliferation and survival of endometriotic ectopic lesions. To test this, 
we utilized matched human eutopic and ectopic endometrium (endometriotic lesions).  We found 
that in endometriotic lesion samples, the majority 52/77 samples) expressed elevated levels of 
RPLP1 mRNA compared to matched eutopic tissues.  RPLP1 protein was also increased in ectopic 
lesion tissue compared to matched eutopic endometrium. In addition, a positive correlation was 
observed between RPLP1 mRNA expression and that of the proliferative marker, cyclin E1 
(CCNE1). To examine the function of RPLP1 in 12Z cells, we knocked down RPLP1 expression 
using siRNA technology and observed a significant decrease in the expression of CCNE1, and a 
concurrent increase in PTEN (a pro-apoptotic marker). In addition, RPLP1 knockdown by shRNA 
demonstrated an approximate 90% reduction in cell survival of 12Z cells compared to those 
infected with non-targeting shRNA. To explore the mechanism of miR-451a in modulating RPLP1 
expression, we conducted a literature review and bio-informatic prediction tools search. This 
revealed that c-Myc was a putative direct target of miR-451a which may potentially regulate 
RPLP1 expression. C-Myc is a transcriptional factor that regulates the expression of many genes 
involved in cell proliferation and tumorigenesis. To investigate the possible regulation of c-Myc 
by miR-451a, we first examined the expression of c-Myc in miR-451a transfected 12Z cells and 
found significant downregulation on the protein and mRNA level. Furthermore, knockdown of c-
Myc by siRNA transfection resulted in a significant reduction of RPLP1 transcript and protein in 
12Z cells.  To examine the relationship between c-Myc and RPLP1 in endometriotic lesion tissue, 
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we first examined the expression of c-Myc transcript in human eutopic and ectopic endometrial 
samples.  We found that the mean fold change of c-Myc expression was four-fold higher in ectopic 
lesions compared to eutopic tissues.  Expression of c-Myc and RPLP1 mRNA were positively 
correlated.  Collectively, these data confirm our hypothesis that RPLP1 is a player in mediating 
endometriotic cell/lesion survival.  In addition, our data revealed a novel pathway which involve 
that miR-451a directly target c-Myc, which in turn may control the expression of RPLP1. 
Outcomes from this research may lead to more specific approaches to treating endometriosis which 
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The endometrium is composed of a functionalis layer, which consists of glandular epithelium 
and stromal cells, that sheds during menstruation, and a basalis layer that contains the stem 
cells which are the source of endometrial tissue and stay intact during menstruation [1]. 
Endometriosis is thought to develop due to “reverse menstruation” of endometrial tissue 
(glands and stroma) through the fallopian tubes, “seeding” of the peritoneal cavity with this 
retrogradely shed tissue and eventual attachment and survival of the tissue.  Lesions are most 
commonly found on the surfaces of the peritoneal cavity, ovaries, and rectovaginal fascia 
(Figure 1). Other less common locations include pericardium, intestines, and diaphragm. 
(Figure 1) [2, 3] .  It is estimated that around 10% of women of reproductive age are affected 
by endometriosis. The condition is mostly associated with pelvic pain and impaired fertility 
[4]. In addition, endometriosis may cause urinary or bowl discomfort to patients due to the 
buildup of the endometriotic lesion tissues on these organs [5, 6]. In the United States, 
endometriosis is considered a major cause of hysterectomy and hospitalization. As a 
consequence, endometriosis affects the quality of life of the affected individual, as well as 
places a financial burden of total annual medical care costs which total around $ 22 billion in 





Figure 1: Endometriotic lesions locations. Endometriosis is characterized by the development 
of ectopic endometrial tissues in different locations outside of the uterine cavity (marked by yellow 
ovals). (Figure was adapted from Blausen.com staff (2014). "Medical gallery of Blausen Medical 



































II. Characteristics, Classifications and Clinical Presentation: 
1. Epidemiology: 
Endometriosis is a chronic disease that affects 5-10% of women of reproductive age [8]. However, 
it is believed that this percentage may be under-estimated. The manifestations associated with 
endometriosis can be undermined by patients and physicians, or confused with other diseases such 
as irritable bowel syndrome (IBS), fibromyalgia, and other chronic pelvic pain syndromes [9]. In 
addition, the only method to confirm presence of the disease is laparoscopy or laparotomy and 
histological confirmation of endometriotic lesions (i.e., endometrial glandular and stromal tissue) 
[10]. Because of these difficulties, many patients with endometriosis are left either un-diagnosed, 
or take longer to get a final and correct diagnosis [8, 11].  Studies conducted in the USA and UK 
assessed the time elapsed from patients’ pain complaint until they are diagnosed with 
endometriosis (via surgical confirmation). These studies revealed that women in USA experienced 
a means of 11.7 years from time of first symptoms to diagnosis of endometriosis, while women in 
the UK experienced a mean of 8 years [8, 11].  Although the time to diagnosis is significantly less 
in the UK compared to the USA, this time frame of approximately 8 years to diagnosis is 
unacceptable. In the US, it is estimated that incidence of the disease is higher in women 25-29 
years of age, and lower in women older than 44 years [12].   
There also appears to be some association, albeit be it weak, with race and endometriosis.  Four 
studies have been conducted, one which suggests that Asian women are more susceptible to 
endometriosis compared to Caucasian [13]. The remaining studies suggest that endometriosis 




2. Endometriosis Classifications:  
Endometriosis is classified into stages based upon the physical characteristics, the location, and 
invasiveness of the lesions [2]. Surgeons use the revised scoring system of the American Society 
for Reproductive Medicine (rASRM) to determine the endometriosis stage [17]. There are four 
endometriosis stages, defined by a point system, that are well- established by the ASRM 
(American Society for Reproductive Medicine). The total points are calculated, and the stage is 
determined accordingly. Staging is initially performed by measuring the number and the size of 
the endometriotic lesions in the pelvic cavity and determining their precise locations. The location 
and the extent of adhesions are also defined, and the maximum score is given to the peritoneal, 
ovarian, and cul-de sac lesions/regions. The identification of endometriosis in vagina, cervix, 
fallopian tube, intestine, and urinary tract and skin are added as in the “additional endometriosis” 
section [17]. Figure 2 shows the procedure used to determine the score based of endometriosis 
lesions in patients. The following list represents the stages of endometriosis [18]:  
• Stage I (Minimal endometriosis): limited number of discrete flat superficial implants in 
pelvic cavity, signs of inflammation around the tissues, and minimal or no signs of 
adhesions (score 1-5 points) [17]. 
• Stage II (Mild endometriosis): superficial patches with adhesion and more inflammation 
(score of 6-15 points)[17]. 
• Stage III (Moderate endometriosis): The most recognizable sign of this stage is the 
development of endometriomas, which are red-brown cysts (chocolate cyst) on the ovaries, 




• Stage IV (severe endometriosis): This stage is characterized by an increase in the number 
and size of deep lesions and chocolate cysts that cause firmer adhesions ( score of > 40 
points)[17]. 
The goal of endometriosis staging is to provide uniform description of the lesions detected in 
laparoscopic diagnosis. However, the usefulness of this system is debated due to several issues. 
There is no correlation made between the characteristics of the lesions and the severity of the 
disease [19, 20]. It is well-known that the stage of endometriosis is irrelevant to the associated 
symptoms; a patient with stage one of endometriosis may experience more intense pain compared 
to a patient with stage four, who may have an asymptomatic form of the disease [20]. In addition, 
the system provides no suggestion to improve treatment options for patients with endometriosis 
[19, 20].  Although far from perfect, the rASRM classification system does allow some degree of 
standardization of endometriosis allowing consistency in classification among different 
physicians. 
The Endometriosis Fertility Index (EFI) is another staging system developed to assess a patient’s  
prospective fertility status after surgical removal of endometriotic lesions [21]. The EFI not only 
includes the rASRM components of endometriosis classification, but also provides a detailed score 
of the fallopian tubes/oviducts, the fimbriae and the ovaries.  The EFI also expands beyond these 
scoring points to include conception-related factors such as age of patient, duration of infertility 
and gravidity history.  However, the use of this system is also controversial because it focuses on 
the fertility aspect of the disease with no consideration to the major complaint in endometriosis 





Figure 2. The guidelines for endometriosis stages and corresponding scores. (adapted from 
Revised American Society for Reproductive Medicine classification of endometriosis: 1996, 



































The majority of women who suffer from endometriosis list chronic pelvic pain (CPP), dyspareunia 
(painful sexual intercourse), dysmenorrhea (painful menstruation), abnormal bleeding, and 
infertility as their chief complaints [4, 8, 22-24].  Endometriosis was confirmed laparoscopically 
in two thirds of adolescent girls with chronic pelvic pain or dysmenorrhea [25]. In the USA, it is 
documented that 79.1% of endometriosis patients  may experience  pelvic pain, 70.2% experience 
dysmenorrhea,  and 49.5% complain of dyspareunia [26]. The associated pain is hypothesized to 
be a result of the estrogenic nature of the disease that increases pain sensitivity, bleeding of the 
extra-uterine lesions, and the ability of the lesions to produce cytokines that stimulate generation 
of nerve fibers, which in turn exacerbates the pain and inflammatory responses [27, 28]. 
Endometriosis patients may take longer to conceive (sub-fertile) or may be unable to conceive 
(infertile). In addition, the prevalence of endometriosis in infertile women is higher compared to 
fertile women [29]. The cause of these findings is not yet understood; however, it is speculated 
that infertility is a result of hormonal imbalance, peritoneal adhesions and extra-uterine 
endometrial lesions [30]. These factors induce changes in the pelvic anatomy and physically impair 
the ovary and fallopian tube functions and cause failure in releasing ovum or capturing it by 
fimbriae, or hindering its passage through the fallopian tube [30]. It is debated whether alteration 
in the physiology of the eutopic endometrium is a cause or a result of endometriosis [4]. It is 
hypothesized that these changes decrease endometrium receptivity, thus lowering implantation 
rates [4]. 
Several other conditions occur as comorbidities with endometriosis including irritable bowel 
syndrome.  Common symptoms of both diseases include nausea, diarrhea, constipation and 




In addition, the presence of endometriotic lesions on the bladder is reported to result in partial 
dysfunction of the urinary tract [6]. 
Studies have linked endometriosis with the onset of depression and anxiety [32]. This may be 
attributed to the chronic pain associated with the disease. A study was conducted to compare the 
psychological stress and depression in three groups: endometriosis patients with pain, pain-free 
patients, and a control group with no endometriosis. The study showed that the quality of life and 
the psychological conditions were compromised in patients who have endometriosis-associated 
with pelvic pain compared to the other two groups [33]. The anxiety and depression in 
endometriosis patients was not correlated with the stage of the lesion nor the age of the patients 
[34]. In addition, it is hypothesized that the mental disturbance in endometriosis patients may 
increase the intensity of the pelvic pain associated with endometriosis, which in turn increases the 
psychological stress [35]. 
4. Diagnosis: 
The diagnosis of endometriosis is a daunting task.  Laparoscopy is the gold standard method to 
detect the lesions [2, 17], but diagnostic laparoscopy is often delayed several years from symptom 
onset. One of the main reasons for the lack of non-invasive diagnostic tools is the lack of 
conclusive knowledge of disease pathophysiology and development. This leads to a delay in 
patient diagnosis considering that invasive method such as laparoscopy is a final step in evaluating 
patients who presented in gynecology offices with pelvic pain and infertility, alarming 





4a. Physical exam and family history: 
The initial criteria for suspected endometriosis are chronic pelvic pain, which is followed by 
obtaining the medical, social, and family history of the patient to rule out or include other 
conditions. In addition, pelvic examination is necessary to check for potential gynecological 
diseases, which feature soreness and focal pain. These characteristics are initiated in 97% of 
patients with pelvic pathology and 66% of endometriosis cases [36]. The similarities of these 
features with other gynecological and abdominal diseases complicate and interrupt the diagnosis. 
Depending on the patient complaints and physician experience, the following methods could be 
used: 
4b. Surgical approach: 
Laparoscopy or laparotomy are the absolute procedures to confirm endometriosis [17]. This is 
performed usually with the isolation of pathological specimens to confirm the presence of 
endometrial tissues; epithelial glands and stoma. In addition, staging of endometriosis is 
accomplished during surgery by following the revised scoring system of the American Society for 
Reproductive Medicine to assess the lesion location, characteristics, color, and invasiveness [2, 8, 
17]. 
4c. Imaging approach: 
There are three methods to detect some forms of endometriotic lesions by radiology, including; 
transvaginal ultrasonography, magnetic resonance imaging (MRI), and Doppler ultrasonography 
[37]. Yet, these provide very restricted access and visualization to a wider area of the pelvic cavity, 
which make them less-than-ideal to exclusively rely to diagnose the disease. Transvaginal 
ultrasonography and magnetic resonance imaging (MRI) have up to 90% specificity in detecting 




peritoneal and ovarian endometriotic lesions and associated adhesions. Likewise, Doppler 
ultrasonography, which estimates the speed and direction of the blood flow through blood vessel, 
provides little information about the presence of lesions. In endometrioma, the insufficient blood 
flow is considered as an indicator that requires further assessment [37].  
Considering these limitations provided by imaging tests, surgical intervention is a necessity to 
acquire a definitive diagnosis of endometriosis. 
5. Treatment and Therapeutic options: 
Endometriosis is a chronic inflammatory disease; and no ultimate cure has been found so far. Thus, 
the available options provided for endometriosis is to alleviate the associated symptoms of pain 
and infertility. 
5a. Pain management: 
i. Pain Medication and hormonal therapy: 
The objective of using a combination of pain medication and hormonal treatment is to control the 
pain in endometriosis patients before diagnostic laparoscopy. The primary approach of therapy is 
the use of nonsteroidal anti-inflammatory drugs (NSAIDs) and combined oral contraceptive [2]. 
Due to the anti-inflammatory effect, NSAIDs such as naproxen are commonly used to decrease 
pelvic pain and dysmenorrhea. However, a recent randomized controlled trial demonstrated that 
there is no evidence in the robust effectiveness of NSAIDs in relieving pain in endometriosis 
patients compared to placebo.  Additionally, the use of NSAIDs was shown to  cause nausea, 
vomiting, headache and other side effects, which make it unfavorable choice to some patients [38].  
Endometriosis treatment depends on the fact that endometriosis is an estrogen-dependent disease. 




such as oral contraceptives (OCPs), aromatase inhibitors, and GnRH analogues [39-43]. 
Alternatively, in severe stages of endometriosis when the available treatments fail to improve 
patient conditions, laparoscopic surgery is performed to remove the ectopic lesions. However, the 
surgical intervention is not the best approach for all patients especially for patients who have severe 
widespread endometriosis, because it may result in partial or complete hysterectomy to eradicate 
the disease. Controlling endometriosis through medications brings more hope for patients to 
improve quality of life and continue their reproductive life [44, 45]. 
Due to low cost and availability, combination estrogen/progestin contraceptives and progestogens 
are used as the primary treatment options for endometriosis patients. These hormones, such as 
medroxyprogesterone (DMPA) and ethinyl estradiol, act in inhibiting ovarian function and 
subsequently in alleviating the pain associated with endometriosis [46-48]. However, there are 
considerable undesirable side effects including preventing pregnancy, depression, nausea, and 
weight gain, which make contraceptives less-favorable for some patients [49] 
Similarly, Dienogest (19-nortestosterone derivative) is a progestin oral contraceptive that is used 
for endometriosis treatment. Dienogest binds to PR (progesterone receptor) with high specificity 
and reduces the level of estrogen,  has an anti-androgenic activity by acting as AR ( Androgen 
receptor) antagonist, and reduces the inflammation and the proliferation of endometriotic cells [50, 
51]. Because of these features, the side effects associated with Dienogest administration are 
considerably lower than other available medications [52]. 
Aromatase inhibitors (AI) are another treatment option for women with endometriosis. Aromatase 
is an enzyme that stimulates the conversion of steroidal precursors to estrogen, has been shown to 




production of estrogen by the lesion tissue. Therefore, inhibiting aromatase activity by AI reduces 
the level of endogenous as well as circulating estrogen levels which regresses endometriotic 
lesions and lessens associated pain [53]. Administration of this medication alone is linked to 
adverse effects. To limit these risks, it is recommended to use AI in a cocktail regime with other 
hormonal therapy such as OCPs or GnRH analogues for endometriosis treatment [54, 55]. 
Gonadotropin - releasing hormone (GnRH) analogs, which block the release of gonadotropin 
hormones and thereby reduce ovarian estrogen production, are a common treatment for 
endometriosis [42]. The reduction in estrogen level limits the growth and the survival of the ectopic 
lesion and suppresses the disease-associated symptoms. Yet, the hypo-estrogenic state introduced 
by GnRHa initiates some side effects such as reduced bone density, hot flashes, sweating, 
psychological disturbances; anxiety and depression. These associated outcomes arise because 
estrogen is necessary in various physiological processes other than uterine development, such as 
bone maintenance and cardiovascular health. As a result, “add-back” therapy is followed to avoid 
these symptoms. A recent comparative study showed that administration of GnRHa together with 
estradiol valerate and norethisterone acetate can mitigate the unfavorable effects and decrease the 
bone loss [56].  However, one must keep in mind that estrogen add-back therapy must be tailored 
to each patient to avoid “flare-up” of lesion growth and return of symptoms.  Clearly, hormonal 
therapy is an important component of endometriosis treatment, but is far from ideal.   
ii. Surgical approach: 
If hormonal therapy fails in relieving pain, surgical intervention is introduced to control the 
symptoms. There are several surgical procedures suggested to manage endometriosis depending 
on the associated symptoms, including laparoscopic excision, laparoscopic presacral neurectomy 




Laparoscopic excision of the lesions performed for patients who did not benefit from medications 
and continue to have pelvic pain including dysmenorrhea and dyspareunia.  At one year after the 
surgery, 90% of patients documented improved symptoms after the laser laparoscopy. However, 
endometriosis has been shown to relapse in 30-50 % of patients five years after laparoscopy. Thus, 
many patients have to go through subsequent surgeries to control the disease [57] [58]. 
In patients with ovarian endometriomas (> 3 cm), drainage and ablation are proposed procedures; 
however, the ideal approach is laparoscopic excision to remove the cysts, control the pain, and 
improve fertility [59]. Nevertheless, there is a considerable chance of damaging the ovaries and 
reducing ovarian reserve. In general, there are some complications that may develop after 
laparoscopic surgeries such as adhesions development, intestinal and bladder injury, nerve injury, 
and gas embolism [60, 61].  
Some patients show low, or no improvements after medical and surgical intervention. Thus, 
laparoscopic presacral neurectomy (LPSN) is performed which involves elimination of the nerve 
fibers around the interiliac triangle. It is considered a third line of treatment in these cases. 
Combination of ablation laparoscopy and laparoscopic presacral neurectomy (LPSN) is a more 
successful approach in reducing the pain and treating primary and secondary amenorrhea [62]. 
Hysterectomy that includes complete or partial removal of the uterus is considered a fourth line of 
treatment when all medical and surgical options have not achieved symptomatic relief. The 
procedure could be also performed in a combination with oophorectomy (removal of ovaries) and 
salpingectomy (fallopian tube removal) [63, 64]. Unfortunately, this aggressive approach is not 
successful in improving the symptoms in all patients. As a result, it is recommended to follow it 




is demonstrated that around 10% of patients re-develop pelvic pain after hysterectomy. This is 
attributed to the potential existence of ovarian remnants and endometriotic lesions, and to the type 
of hysterectomy performed [65, 66]. 
Due to the complications associated with the surgical interventions and the need for follow-up 
medicated regime afterward, the necessity for non-invasive options to treat the disease have been 
proposed in several studies. 
5b. Infertility management: 
Infertility in endometriosis arises from several hormonal and physiological disturbances caused by 
the growing lesions. In addition, the available treatment options to alleviate the pain aim to target 
the ovarian hormonal pathway, which creates another issue of pausing a woman’s fertility. Thus, 
many endometriosis patients require medical assistance to conceive, which is achieved through 
medications and assisted reproductive technologies (ART).   
6. Risk factors: 
There are certain factors that are assumed to increase or decrease the risk of endometriosis. Most 
of these factors represent recommendations to maintain healthy life in general and not related to 
endometriosis only [10, 12]. 
6a. Physiological factors: 
One of the most important factors is an early age at menarche, which is expected to increase the 
risk of endometriosis [12] . Early puberty and menstruation, in addition to obstruction of menstrual 
outflow, such as in Müllerian anomalies, impose a hormonal alteration that persists longer in those 
women. More importantly, the higher level of circulating estrogen initiates a favorable 




and survival [67]. There is also a positive association of endometriosis and lower BMI (Body Mass 
Index), which is demonstrated by higher tendency of lean women to develop the disease [10, 68-
70]. Interestingly, the incidence of endometriosis is increased in women who were born at low 
birth weight [71]. Furthermore, short menstrual cycle is another factor that is expected to increase 
the risk of endometriosis [10, 70, 72]. 
6b. Pregnancy and breastfeeding: 
Women who have given birth one or more times are at a lower risk of developing the disease 
compared to nulliparous women, which is attributed to increased level of circulating estrogen [16, 
73]. Furthermore, breastfeeding was found to be associated with lower endometriosis 
susceptibility, which is explained by the postpartum amenorrhea and reduction in the level of 
gonadotropins [74] .  
6c. Oral contraceptive: 
Oral contraceptive use is associated with low risk of endometriosis. However, considering that 
endometriosis is controlled by hormonal oral contraceptives, it is not well-known if the lack of 
endometriosis symptoms in these women is due to the suppression of ectopic lesions, because of 
these medications, or due to the definitive free-disease state [75]. 
6d. Life style: 
Following a healthy life style; consumption of fruits, vegetables, fish, and omega-3 fatty acids, in 
addition to regular exercise are associated with decrease risk of endometriosis [72, 76] . Exercise 
and omega-3 fatty acids are demonstrated to decrease the level of inflammatory markers including 




assumed to stimulate implant establishment. In contrast, consuming alcohol is linked to increased 
disease development [12, 78]. 
Likewise, cigarette smoking is suggested to reduce the incidence of endometriosis [72]. This 
surprising data might be explained by a study that demonstrated that the anti-estrogenic effects of 
nicotine [79, 80] may suppress lesion survival and manifestation of symptoms.  Although the 
rationale behind this observation is reasonable, other groups revealed contradicting results and 
showed that cigarette smoking was not associated with the prevalence of the disease [81, 82]. 
6e. Genetic predisposition: 
The involvement of a genetic factors in endometriosis development is debated. Yet, the available 
data suggest that there are genetic variants that need to be considered and investigated. Several 
studies demonstrated there is higher incidence between siblings and daughters of mothers 
diagnosed with endometriosis. In addition, cases of endometriosis in twins provided further 
evidence that supports the interplay between endometriosis and genetic make-up [83]. The 
difficulties of pointing out the potential genetic variant are due to the lack of large confirmed cases 
and the heterogeneity of the lesions. There are approximately 76 candidate genes that are expected 
to be associated with endometriosis [83]. Most of these genes are responsible for inflammatory 
disorders, and regulation of steroidal mechanisms.  For example,  interleukin 6 (IL-6), interleukin 
10 (IL-10),  signal transducer and activator of transcription 6 (STAT6), cytochrome P450, family 
1, subfamily A, polypeptide 1 (CYP1A1), progesterone receptor (PGR), tissue inhibitor of 
metalloproteinases-2 (TIMP2),  and epidermal growth factor receptor (EGFR) have all been 
associated with endometriosis [83]. These data agree with the origin of endometriosis because it 
is a chronic inflammatory and estrogen-dependent disease. Furthermore, genetic linkage to 




to be significant in studies conducted among sisters and twins in Australian and UK research 
groups [84].  
6f. Environmental factors: 
The development of endometriosis due to various environmental stimulants is controversial. It is 
speculated that organochlorines play a role in endometriosis pathogenesis [85-88]. 
Organochlorines (known as dioxins) are a group of structural and functional related elements that 
are composed of chlorines as main structure. Examples of different types of organochlorines are 
pesticides such as DTT (dichlorodiphenyltrichloroethane) and industrial by-products such as 
polychlorinated biphenyls (PCBs), polychlorinated dibenzodioxins (PCDDs), and polychlorinated 
dibenzofurans (PCDFs) or furans [86, 89].  PCBs are used in industrial products such as 
transformers, oil-based paints, plastics, and appliances.  Because of its features in providing 
firmness, electrical insultation, and resistance to flame, is used widely in manufacturing. However, 
the structure of dioxins contains a high number of chlorine atoms making it a source of toxicity in 
humans and in the environment. Thus, the usage of PCBs in manufacturing is banned in United 
States, still, the leaked remnants in air, food, or soil from old products is considered an 
environmental and health hazards [86, 90, 91]. Leaked PCBs are carcinogenic materials absorbed 
by skin and gastrointestinal and cause illness in the reproductive system, nervous system, 
endocrine system, and liver [92]. 
The contribution of dioxins in endometriosis development is based on the observation that dioxins 
may bind to estrogen and androgen receptors, promote the activity of estrogen, and consequently 
stimulate the growth of endometriotic lesions [87, 93, 94]. In addition, dioxins were found to cause 




The level of dioxins, for instance PCBs, in endometriosis patients’ samples was examined in 
several studies and found to be significant compared to control women, and the level was also 
associated with the stage of the lesion [96, 97]. However, other groups demonstrated that the 
concentration of organochlorine in serum of diseased and control women was insignificant [98, 
99]. Indeed, these contradicting findings ignite the debate of whether dioxins are a promoter for 
endometriosis or not. 
II. Endometriosis Pathogenesis: 
The pathophysiology of endometriosis is not well-understood. Therefore, the availability of less-
invasive diagnoses and more specific treatment options are limited. Several theories have been 
proposed to explain the origin of the disease. One of the first theories was based on the speculation 
that the ectopic endometrial tissue is transformed from normal peritoneal tissue; coelomic 
metaplasia [100]. The transformation of the tissues is explained to be caused by stimulatory 
factors, hormonal or immunological [101-104]. The metaplasia theory suggests the differentiation 
of bone marrow stem cells, mesenchymal stem and endothelial stem progenitors into endometriotic 
tissue [105]. Furthermore, it has been hypothesized that endometriosis is developed as a result of 
benign metastasis which originates from the circulation of the endometrial cells in blood and 
lymphatic systems [106]. Immunity imbalance is expected to cause the development of the ectopic 
endometrial lesions because of the statistics that show that autoimmune disease is more prevalent 
in women with endometriosis [101, 107-109]. Although these theories may provide insight into 
the origin of the disease, the mechanism of the migrating, attachment, and surviving of 
endometriotic lesions ectopically is not well-explained. Thus, evidence to support these theories 
and investigate pathways of lesion establishment are examined by studying the differential 




women.  Theories of endometriosis development, and the transcriptomes and proteomic alterations 
are explained in detail below: 
  1. Retrograde Menstruation: 
Retrograde menstruation is the most widely accepted theory for the development of  endometriosis 
[14]. According to this theory, during menses, a portion of the endometrial lining is also shed 
retrogradely through the fallopian tubes into the peritoneal cavity.  Retrogradely shed endometrial 
fragments attach in the pelvic cavity leading to the implantation and development of endometriotic 
lesions [14].  It is estimated that around 70%-90% of women of reproductive age encounter 
retrograde menstruation, however, only a few (approximately 10%) of these develop endometriosis 
[110]. This theory is supported by the existence of endometrial debris in the pelvic cavity of 
patients with endometriosis compared to healthy women and by  the reduction of endometriotic 
lesions in women who were treated by endometrial ablation that involves destruction of the 
endometrium [111]. Moreover, endometriosis induction was established in non-human primates, 
baboons and macaques, which develop spontaneous endometriosis through inoculation of 
endometrial tissue into the pelvic cavity. The development of the ectopic endometriotic tissues, 
which are morphologically similar to human endometriotic lesions, are successful in 40% of the 
baboon model after one inoculation, and in 100% of the baboons after double inoculations. [112, 
113]. Donnez and colleagues [114] induced the two layers of the endometrium (functionalis and 
basalis) ectopically in the animal model, which leads to the development of deep nodular 
endometriosis. The regeneration of endometrium is thought to be from stem cells located in the 
basalis; however, only the upper layer of functionalis sheds during menstruation. Therefore, this 
model may not recapitulate the actual process of retrograde menstruation. In women with 




internally, the risk of endometriosis is increased which is attributed to the larger amounts of 
sloughed endometrial tissues to the peritoneal cavity, which is an indication of the rationality of 
the retrograde menstruation theory [100]. 
Although the theory of retrograde menstruation is widely supported, it doesn’t explain 
observations of endometriosis in men and pre-pubertal girls [110, 115, 116]. Also, it doesn’t 
provide explanations of the factors that make these women more susceptible to develop the disease 
and promote lesion survival and proliferation. If this theory is true, we still have several gaps to 
fill to understand exactly how the migrated ectopic lesions escape the “immune-surveillance” 
system, and what mechanisms contribute to the growth, angiogenesis, and establishment of the 
implants. 
2. Metaplasia: 
The metaplasia theory proposes that endometriosis is established because of transformation of 
normal epithelial cells or undifferentiated cells into ectopic endometriotic lesions, and this is 
represented by coelomic metaplasia, and trans-differentiation of Wolffian or Mullerian ducts in 
female embryos [117]. Coelomic metaplasia is the process of transformation of celomic epithelia 
cells that line the abdominal organ and abdominal wall into endometriotic lesions, under the 
influence of estrogenic and inflammatory stimulants [117]. Trans-differentiation of Wolffian or 
Mullerian ducts theory suggests that the endometrial cells outside of the uterus are generated 
originally from imperfect growth of Wolffian or Müllerian ducts during embryonic development. 
This theory speculated that ectopic endometrial lesions are developed as a result of Wolffian or 
Mullerian duct remnants which progress into estrogen-responsive lesions [100]. Although these 
theories may provide some explanations to the establishment of endometriosis in pre-pubertal girls 




addition, the observations of endometriotic implants outside of the pelvic cavity was not taken into 
consideration. 
3. Immunity dysfunction: 
The theory of immunity dysfunction was developed due to the observation that women with 
endometriosis show high levels of activated macrophages, and decreased activity of natural killer 
cells [103, 118]. According to this theory, the buildup of the endometrial tissues in the peritoneum 
stimulates the inflammatory response, leading to the local activation of macrophages and 
leukocytes [103, 118]. However, due to the defective immunity, the recruited inflammatory factors 
fail to be recognized by the immune response. This leads to the growth and establishment of the 
ectopic lesions causing endometriosis [101].   
4. Stem cells: 
Stem cells are undifferentiated cells that are capable of self-renewal and differentiation into certain 
types of cells under specific stimuli. The development of endometriosis as a result of stem cell 
translocation to the perirenal cavity is supported by the evidence of the presence of fractions of 
basalis layer in the ectopic lesions.  Basalis layer consists of  clonogenic cells that are the source 
of endometrial tissue renewal, however, this layer doesn’t shed during menstruation [1]. The 
observation of the existence of clonogenic cells and endometrial cells in ectopic lesions provides 
evidence of a potential role of stem cells in endometriosis development [119]. Based on these 
observations, it is hypothesized that during menstruation, a portion of basalis layer is also shed 
with the endometrial tissue retrogradely, and the stem cell components can differentiate into 
endometriotic lesions [120].  Supporting this theory, endometriotic lesions in baboons were 
successfully established in 100% of the animals through implantation of a pool of endometrial 




it doesn’t provide an explanation for the regeneration of endometriotic lesions in locations other 
than pelvic cavity. Therefore, the migration of bone marrow stem cells through the lymphatic 
system to remote sites was suggested to fill this gap [121, 122].  
5. Transcriptome and proteomes alterations: 
Changes in mRNA and protein levels in eutopic endometrium, ectopic lesions, peritoneal fluid, 
and serum of endometriosis patients are hypothesized to be a cause of endometriosis [123]. Yet, 
several studies suggested that these alterations may develop as a result of the disease [124]. Thus, 
the findings of these observations are proposed to provide diagnostic biomarkers and/or 
therapeutic targets. On the transcriptome level, the deregulation of miRNAs has also been 
investigated as a cause or result of endometriosis [125-131].   . 
5a. miRNAs:  
miRNAs are short non-coding nucleotide sequences that regulate the expression of target genes 
[132, 133]. The biogenesis of miRNA transcript is initiated in the nucleus under the direction of 
polymerase II or III to form the long primary RNA transcript (pri-miRNA)[134] . The capped and 
poly-adenylated pri-miRNA forms a complex by binding to the RNA-binding protein DGCR8 
(DiGeorge syndrome critical region 8) [135-137]. This is followed by the action of Drosha (an 
RNAse III enzyme) that cleaves pri-miRNA–DCGR8 complex to make pre-miRNA, a stem-loop 
precursor [138, 139]. The pre-miRNA is transported into the cytoplasm and undergoes under 
another cleavage by DICER, RNAse III enzyme, which cleaves the pre-miRNA into an RNA 
duplex [140].  The generated strands of the miRNA duplex go through different pathways; one 
strand is degraded and the other strand binds to RISC, the RNA-induced silencing complex [140]. 
This creates the mature miRNA which recruited RISC to suppress gene transcription by binding 




may also induce repression by binding to the coding sequence or the 5’UTR of gene targets, a less 
common mechanism [143, 144]. Of all miRNAs, the only exception to this pathway is miR-451 
(now known as miR-451a), which is cleaved into RNA duplex by Ago2 protein and continues to 
form mature miR-451a, independently of DICER action [145-147].  Figure 3, represents the two 
pathways of miRNA biogenesis, a canonical pathway of miR-144 and Dicer-independent pathway 
of miR-451a [147]. 
 miRNAs are essential in the normal development of tissues, thus, alteration in expression is 
associated with several diseases including cancer, inflammatory and auto-immune diseases [148-
151]. In endometriosis, there are several studies that hypothesized the role of miRNA in the 
pathophysiology of endometriosis [125-131].  The expression profile of mis-expressed miRNAs 
in endometriotic lesions, eutopic tissues, and eutopic endometrium from disease-free women has 
been reported by several research groups [152-156]. One of the most differentially expressed 
miRNA is miR-451a, which was shown by microarray analysis to be two-fold lower in 
endometriosis samples (eutopic endometrium and ectopic lesions) compared to endometrial tissues 
from women without endometriosis [152]. Further studies using next-generation sequencing 
technology demonstrated that miR-451a is up-regulated in ovarian endometrioma compared to 
eutopic endometrium [154]. It is proposed that miR-451a acts as a tumor suppressor and reduces 
cell survival by targeting genes responsible for cellular proliferation, apoptosis, and invasion [131, 
157-162]. Evidence of this role was established in endometriosis using bioinformatic prediction 
tools, PCR, western blot, and reporter assay [131, 157-162].  
Previously in our laboratory, miR-451a was demonstrated to be elevated in endometriotic lesions 
and reduced cell proliferation by directly binding to the 3’UTR of MIF (macrophage inhibitory 




factor for human endothelial cells in vitro and tumor angiogenesis in vivo [163]. Yang and 
colleagues demonstrated that, in patients with endometriosis, MIF could stimulate endothelial cell 
proliferation [164]. Further supporting a role of MIF in endometriotic lesion survival, MIF has 
been shown to stimulate PGE2, COX-236, vascular endothelial growth factor (VEGF), interleukin-
8 (IL-8), and monocyte chemotactic protein-1 (MCP-1) expression [165], as well as the induction 
of aromatase expression in a feed-forward mechanism [166]. Interestingly, MIF also stimulates 
TNF-α secretion, whereas TNF-α is also capable of inducing MIF production in endometrial cells 
[167]. Also, of relevance to the pathophysiology of endometriosis is the demonstration that many 
of these MIF-induced factors are associated with a proliferative and angiogenic phenotype 
conducive to endometriotic establishment or growth (or both) [165].   
Furthermore, Joshi and colleagues induced endometriosis in baboons and found reduced 
expression of miR-451a in the baboon’s eutopic endometrium [131]. In the endometriotic 
epithelial 12Z cell line, miR-451a was found to directly target and repress the YWHAZ gene [131], 
which codes for 14.3.3ζ (zeta) protein, causing a reduction in cell survival and proliferation [131]. 
14.3.3ζ protein plays a role in signal transduction and it regulates tumorigenesis and apoptosis 
[168, 169]. 
Preliminary data from our laboratory demonstrated that RPLP1, ribosomal protein large P1, may 
serve as a potential target of miR-451a. RPLP1, ribosomal phosphoprotein large P1, is part of the 
60S ribosomal subunit. The RP (ribosomal proteins) composed of one RPLP0 and two 
heterodimers of RPLPL1 and RPLP2 that form the ribosomal stalk (Figure 4)[170-173].  P1 and 
P2 share similar molecular mass of 12 kDa and form a structure that play a role in translation 




elongation step of protein synthesis, the phosphorylated forms of P1 and P2 promote the GTPase 
activity of eEF‐2 which stimulates the translocation of peptidyl‐tRNA from the A to the P site 
[177]. P1 and P2 were also detected to be free in the cytoplasm and it speculated that an exchange 
occurs between the two status (free and ribosome bound) to modulate the translation process [176].  
Although most of the research on ribosomal function of RPLP1 focus on its role in translation, few 
studies have evaluated additional functions.  RPLP1 has been speculated to play a role in 
tumorigenesis. RPLP1 is highly expressed in gynecological tumors and stimulates cellular 
transformation [178]. In some ovarian cancers, the level of RPLP transcripts was found to be 
related to the p53 levels [178, 179].  Additionally, a study was conducted to examine the RPLP1 
mechanism responsible for cell development and growth, which demonstrated that downregulation 
of RPLP1 caused endoplasmic reticulum (ER) stress and promotes autophagy [180]. Furthermore, 
Compao and colleagues found that RPLP1and RPLP2 are essential host factors for replication of 
flavivirus, dengue viruses (DENV), yellow fever virus (YFV), and Zika virus (ZIKV) [181].  This 
study demonstrated that these viruses utilize both host proteins, RPLP1 and RPLP2, for viral 
protein translation, an important step to replicate inside human cells.   
With respect to the role of RPLP1 in endometriosis, we are not aware of previous studies that 
correlate RPLP1 expression with that of endometriosis. However, the dysregulation of ribosomal 
RNAs and proteins expression in endometriosis has been reported [182-186]. Specifically, 
ribosomal protein L26 was one of the 91 up-regulated genes detected in eutopic endometrium from 
endometriosis patients compared to endometrium from women without endometriosis [185]. 
Additionally, expression of ribosomal protein S14 (RPS14) and ribosomal protein S9 (RPS9) is 
elevated in endometriotic lesions taken from patients with endometriosis versus endometrium from 




lesions compared to paired endometrium tissues, was also found in a study conducted by Wei-Ping 
Hu and colleagues [184] and included ribosomal protein L7 (RPL7), ribosomal protein S17 
(RPS17), ribosomal protein L9 (RPL9), ribosomal protein S4, X-linked (RPS4X), ribosomal 
protein S25 (RPS25), ribosomal protein L10a (RPL10A), ribosomal protein L41 (RPL41), and 
ribosomal protein L13a (RPL13A) [184]. Defects in ribosome biogenesis was suggested to 
promote endometriotic lesions development because of mis-expression of ribosomal proteins in 
endometrial tissues of patients with endometriosis [183]. Outside of these descriptive data, no 
mechanistic studies have been performed to evaluate a potential functional role of ribosomal 





Figure 3. Representation of the miRNA canonical pathway biogenesis and miR-451 dicer-
independent pathway. (Adapted from A. Dueck, G. Meister, MicroRNA processing without 


























Figure 4. The interaction of ribosomal proteins P1, P2, and P0 to form the ribosomal stalk.  
(Adapted from W.J.L. Maximiliano Juri Ayub, Johan Hoebeke and Cristian R. Smulski Ribosomes 
from Trypanosomatids:  Unique Structural and Functional Properties Cell-Free Protein Synthesis 




























































Objective of the research: 
Endometriosis is an estrogen – dependent, debilitating disease, defined as the development of 
ectopic endometrial tissue, which establishes primarily in the pelvic cavity. The primary symptoms 
of the disease are pelvic pain and infertility [10]. Endometriosis is speculated to develop by 
retrograde menstruation in which endometrial fragments travel retrogradely through the fallopian 
tubes[14].  However, because essentially all women exhibit some degree of reverse menses, some 
other factors must lead to endometriosis in the subset of women who develop this disease [14].  
The uncertainties about the development, as well as the establishment and progression of the 
disease have led to an inadequate ability to effectively treat the disease.  One well-established fact 
is that estrogen is essential for endometriotic lesion survival.  Thus, current treatment options target 
the suppression of the estrogen responsiveness of the tissue, which reduces the burden of the 
disease [187] .  While suppression of estrogen action and or production is effective in many 
women, it is associated with unwanted and potentially detrimental negative side effects [28, 188]. 
Collectively, these shortcomings highlight the necessity for a better understanding on the 
pathogenesis of endometriosis so that more specific treatments with fewer side effects can be 
developed. Initial studies from our laboratory demonstrated that miR-451a plays a role in 
endometriosis pathogenesis through regulating the expression of several gene targets including 
RPLP1, Ribosomal Protein Large P1. Furthermore, we found that RPLP1 is highly expressed in 
the ectopic endometriotic lesions compared to the eutopic tissues.  RPLP1 is a ribosomal protein 
that contributes to cellular proliferation, transformation, and tumorigenesis [178, 179, 189]. As 
this protein has been proposed to play a pro-survival role in diseases associated with enhanced 
tissue survival and proliferation, we propose that the elevated expression of RPLP1 in 




overall objective of our research is to examine the function and the expression of RPLP1 in 
endometriotic lesion tissue as well as its relationship with, and potential regulation by miR-451a.  
The following study is the first to identify the differential expression of RPLP1 in endometriotic 
lesions compared to matched eutopic endometrium as well as with endometrium from control non-
endometriosis patients. The outcomes from this study have significant potential to deepen our 
understanding on critical modulators of endometriotic lesion survival which ultimately may 
translate into novel treatments for endometriosis which minimize or eliminate unwanted side 
effects.  Additionally, development of novel approaches for endometriosis treatment which exhibit 
minimum alteration to the estrogen pathway will reduce the occurrence of the menopause like 












Chapter II:    
RPLP1 Is a Novel Target of miR-451a Whose Expression Is Elevated in 
Endometriotic Lesion Tissue and Correlates with Endometriotic Lesion 







INTRODUCTION: Endometriosis is a disease common in women of reproductive age where 
endometrial tissue establishes and survives in ectopic locations. However, how these lesions 
establish and survive is unknown. We have recently identified ribosomal protein large P1 (RPLP1; 
which is a modulator of cell proliferation) as a potential target of miR-451a expressed in 
endometriotic epithelial 12Z cells. The objective of the current study was to determine the 
expression of RPLP1 in human endometriotic lesion tissue, examine the function of RPLP1 in 
modulating cell survival/proliferation and miR-451a regulation of RPLP1 expression. 
METHODS: RPLP1 mRNA and protein levels were examined in paired endometriotic lesion 
tissue and eutopic endometrium from women with stage III/IV endometriosis (N=55) as well as 
tissue from women without symptoms of endometriosis (controls; N=30 for localization studies). 
RESULTS: Net expression of RPLP1 mRNA was significantly higher in ectopic lesion tissue 
compared to paired eutopic endometrium (3.72-fold increase; P<0.01) and immunohistochemical 
localization revealed predominant localization to epithelial cells (lesion > endometriosis eutopic > 
control eutopic; P<0.05). As RPLP1 is proposed to drive cellular proliferation, we assessed the 
correlation between lesion RPLP1 mRNA expression and that of cyclin E1 and observed a positive 
correlation between both markers (Pearson r = 0.571; P<0.01; N=69). To further demonstrate 
functionality, we generated a stable 12Z cell line in which RPLP1 was deleted and found that loss 
of RPLP1 expression was associated with a 90% reduction in cell number/survival (P<0.001; 
N=3). We further demonstrated that over-expression of miR-451a via transient transfection of 12Z 
cells resulted in a significant (P<0.05; N=3) reduction in RPLP1 expression as well as that of cylcin 




CONCLUSIONS: These studies reveal that RPLP1 is a novel target of miR-451a and that RPLP1 
expression and its regulation by miR-451a are associated with cell proliferation and survival. 
These results, as well as our previous and ongoing studies, continue to support a role for miR-451a 
in modulation of endometriotic lesion tissue/cell survival which may prove useful as a non-






Endometriosis is a chronic inflammatory disease, characterized by the development of ectopic 
endometrial tissue, which establishes primarily in the pelvic cavity. The primary symptoms of the 
disease are pelvic pain and infertility [100]. Endometriosis is thought to develop through “seeding” 
of the pelvic cavity via retrograde menstruation of shed endometrial tissue during menses [14]. 
The mechanism that induces the migration, attachment, and survival of these lesions is not well- 
understood. However, several theories have been proposed to explain the origin of the disease.  
One of the  potential mechanisms for the development and/or survival of endometriotic lesions 
tissue was based on microarray analysis of ectopic lesions and eutopic tissues from endometriosis 
patients and women without endometriosis [152]. The result of the study illustrated several 
miRNAs that are differentially expressed in these tissues that may contribute to endometriosis 
pathogenesis. MiRNAs are conserved short nucleotides sequences that regulate the expression of 
their target genes and play a dynamic role in many biological and pathological processes [141].  In 
endometriosis, miRNAs have been demonstrated to control the expression of genes responsible of 
proliferation, cellular migration, and apoptosis. Above all, miR-451a has been recognized as one 
of the most mis-expressed miRNA between eutopic tissue and ectopic lesion of patients with 
endometriosis and eutopic tissue from disease-free women [152].  The level of miR-451a was 
speculated to be negatively associated with ectopic lesion survival and growth through modulating 
the expression of certain genes; MIF [128], fibrinogen alpha chain [128], and YWHAZ [159]. In 
a baboon model, induction of endometriosis was found to decrease the expression of miR-451a at 
3 months post-induction and this was correlated with the elevation of its target gene, YWHAZ. 




that miR-451a expression is mainly in the epithelium (glandular and luminal) compared to the 
stroma [131].  
While the expression of miR-451a in human endometriotic lesion was confirmed, the exact 
mechanism by which miR-451a might reduce lesion aggressiveness is still uncertain. As such, the 
objective of the current study was to investigate the role of miR-451a in endometriosis.  To do so, 
we began by screening differential proteins expression in endometriotic epithelial 12Z cells in 
which miR-451a was over-expressed.  From the dozens of potential targets of miR-451a, we 
initially focused on RPLP1 (Ribosomal Protein Large P1). We selected RPLP1 as this protein has 
been associated with endometrial cancer [179]; a disease which shares similar characteristics with 
endometriosis in which cell migration, attachment and survival is enhanced.  For the current study, 
we focused on evaluating RPLP1 mRNA and protein expression, examining its regulation by miR-





Materials and Methods 
 
Cell culture and transfection for miR-451a assessment 
 For our in vitro studies, we used the well-characterized endometriotic epithelial cell line, 12Z 
(159) which were obtained from Dr. Linda Griffith, MIT via a Materials Transfer Agreement 
(MTA).   
 12Z cells were seeded at density of 1 × 106 cells/ml of media in T-75 flask using complete 
culture media: phenol red-free Dulbecco's Minimum essential medium (DMEM)/Ham's F12 
(Sigma Chemical Co.) + 10% charcoal stripped FBS (Atlanta Biologicals, Atlanta, GA, USA) + 
Pen-Strep (Sigma Chemical Co) for maintenance. Once the cells reached approximately 90% 
confluency, the cells were passed and plated in 6 wells plates at a density of  1 × 105 cells/ml in 
phenol red-free Dulbecco's Minimum essential medium (DMEM)/Ham's F12 (Sigma Chemical 
Co.) with no FBS and P/S added and placed in the incubator for 24h at 37C and 5% CO2.  
For transfection assays: After 24h of plating the cell, 12Z cells were transfected using 
Lipofectamine 2000 transfection agent (Life Technologies/Ambion, Inc.) following the 
recommendations of the manufacturer with either Lipofectamine 2000 transfection reagent 
mixed with 30 nM of pre-miR451 (pre451; Life Technologies/Ambion, Inc., Grand Island, NY, 
USA) or a non-targeting mimic (NT-mimic, negative control; Life Technologies/Ambion, Inc.). 
At 24h and 48h post-transfection, RNA and proteins were collected for qRT-PCR, western blot, 
and 2D-gel analysis.  
For RPLP1 transient knockdown, siRNA (small interfering RNA; Dharmacon: ON-TARGET 




in phenol red-free DMEM: F12 containing 10% non- charcoal stripped FBS, 1% Pen-strep. As a 
control, non-targeting NT siRNA cDNA was used. For RPLP1 knockdown, Cells were transfected 
using siPORT™ NeoFX™ transfection agent (Life Technologies/Ambion, Inc.) following the 
recommendations of the manufacturer.  Briefly, transfection reagent was mixed with 50 nM siRNA 
cDNA for RPLP1 and added to 6-well plates (.2ml volume). Then, the 12 Z cells (1 × 105 cells in 
1.8 ml of complete media) was added to the plates and cultured for 24, 48, and 72h. For each 
treatment, cells were cultured in duplicates and then processed for proliferation/survival 
assessment, and for protein analysis. After each time point, the medium was removed and the 
number (percentage) of the dead cells was evaluated. The live cells (viable) were collected by mild 
trypsin digestion and then trypan blue dye was added to estimate the cells number and viability. 
All assessments were performed in duplicate and this experiment was repeated at least 4 times 
using different passages of the 12Z cells.  
For stable knockdown of RPLP1 in endometrial 12Z cells: To develop stable RPLP1 deficient 
cell lines, 12Z cells were plated at 1 × 105 cells/well of 6-well plates in DMEM:F12 with pen/strep 
and 5% FBS for 24h. Cells were transduced with either lentiviral particles expressing a shRNA for 
RPLP1, or a non-targeting shRNA (negative control) per the manufacturer's instructions 
(GeneCopoeia, Inc., Rockville, MD).  Cells were then cultured with puromycin (2 µg/mL) to select 
positively infected cells.  These stably transfected cells were maintained for experimentation or 
stored in liquid nitrogen for future experiments.  
2D gel analysis 
2D-DIGE (2-dimensional differential in-gel electrophoresis) was performed by Applied Biomics 




451a or pre-NT transfected (as described above) using lysis buffer (Cell Signaling Technology, 
9803) and .5% PMSF.  For 2D-DIGE and Mass spectrometry, the extracted Protein samples were 
sent to Applied Biomics (Hayward, California). The experiment was performed using SDS 
(sodium dodecyl sulfate) polyacrylamide gel electrophoresis by Typhoon TRIO (GE Healthcare). 
The image was scanned using by Image QuantTL 8.1 software (GE Healthcare-Biosciences, 
Pittsburgh, Pennsylvania) and analyzed (in-gel and cross-gel analysis) using DeCyder software 
version 6.5 (GE Healthcare) to identify the differential expressed proteins. The ratio changes of 
the protein differential expression between pre-miR-451a and pre-NT transfected cells in which 
protein expression was >1.5-fold were selected (25 protein total).   Proteins were then isolated 
using Ettan Spot Picker (GE Healthcare) and subsequent MALDI-TOF (MS) and TOF/TOF 
(tandem MS/MS) using a 5800-mass spectrometer (AB Sciex). 
For protein identification, the resulting peptide mass and the associated fragmentation spectra were 
submitted to GPS Explorer version 3.5 equipped with MASCOT search engine (Matrix Science) 
to search the database of National Center for Biotechnology Information non-redundant (NCBInr). 
Searches were performed without constraining protein molecular weight or isoelectric point, with 
variable carbamidomethylation of cysteine and oxidation of methionine residues, and with one 
missed cleavage allowed in the search parameters. Candidates with either protein score C.I.% or 
Ion C.I.% greater than 95 were considered significant. All proteins reported in this work had a 
C.I.% of 100%.   
RNA isolation and qPCR 
 
For assessment of mRNA, total RNA was isolated using the Tri-reagent (Sigma Chemical Co., St. 




RT kits (Applied Biosystems; Foster City, CA, USA), according to the manufacture instructions. 
Primer-Blast was used for primers design, and for 18S (control). The primer used in this study are 
RPLP1 V1: forward 5’-TGACAGTCACGGAGGATAAGA-3’, reverse 5’- 
CCAGGCCAAAAAGGCTCAAC-3’. RPLP1 V2: forward 5’-CTCACTTCATCCGGCGACTA-
3’, reverse 5’-GCCAGGGCCGTGACTGT-3’. CCNE1: forward 5’-CAGGGAGCGGGATGCG-
3’, reverse 5’-GGTCACGTTTGCCTTCCTCT-3’. PTEN: forward 5’-
AAGACATTATGACACCGCCAAA-3’, reverse 5’-GTGGGTTATGGTCTTCAAAAGGA-3’. 
The primers were synthesized by Integrated DNA Technology (IDT, Coralville, IA). The resulting 
samples were used for qRT-PCR by using QuantStudio 7 Flex System. All samples were run in 
triplicate, and the calculation was done by using the average values, and the 2-delta-delta CT 
method. In human tissues experiment analysis, human 18S primers probe reagents were analyzed, 
and the fold changes were normalized to the eutopic endometrium. In 12Z human endometriotic 
cells experiment analysis, human 18S primers probe reagents were analyzed, and the fold changes 
were normalized to the non-targeting (negative control).  
For miR-451a qRT-PCR analysis, total RNA of (250 ng in 5 µl) was reverse transcribed using 
miR-451a Kit (Applied Biosystems) and RT kits (Applied Biosystems) according to manufacture 
protocol. An individual reverse transcription was performed using 2 ul from each miRNA 5X RT 
primers. Using the resulting material, individual qRT-PCR for each specific miRNA using 
QuantStudio 7 Flex System. All Samples were tested in triplicates and normalized to U58 (control) 






Protein Isolation and Western blot:  
 
The human tissues were homogenized in RIPA Buffer (Cell Signaling Technology, 9806) with 
PMSF (Cell Signaling Technology, 8553S) and total protein concentration measured using Bio-
Rad by Protein Assays ([Catalog 3500-0006], Bio-Rad Laboratories, Richmond, CA, USA).  
To isolate the protein from the 12Z human endometriotic epithelial cell line, the protein was 
isolated by using lysis buffer (Cell Signaling Technology, 9803) with PMSF (Cell Signaling 
Technology, 8553S), and then the Bio-Rad Protein Assay ([Catalog 3500-0006], Bio-Rad 
Laboratories, Richmond, CA, USA) was used to determine the total protein.  
The same amount of protein (50 µg) was electrophoresed through 12% Bis (2-hydroxyethyl) 
amino-tris(hydroxymethyl)methane (w/v) gels and electro-blotted onto nitrocellulose membrane 
(Invitrogen). Primary antibody (RPLP1 1:500; ProteinTech 216363-I-AP) and goat anti-rabbit 
secondary antibody (1:5000; GE Healthcare/Fisher Scientific, Pittsburgh, PA, USA) were used. 
To normalize the protein expression levels, stripping and re-probing for beta-actin (ab8227) 
(Abcam, Cambridge, MA, USA). The immuno-detection was performed by using enhanced 
chemiluminescence (ECL) kit (Thermo Scientific, Waltham, MA, USA). 
Human Tissues 
 
We utilized tissue samples from our IRB-approved bank of specimens which were obtained from 
the University of Kansas Medical Center, Department of Pathology and Laboratory Medicine 
and/or the Department of Obstetrics and Gynecology at the Cleveland Clinic.  This consists of 
paraffin-embedded tissue sections for immunohistochemistry studies as well as frozen tissue for 




Samples were obtained from subjects between the ages of 21 and 45 who presented with pelvic 
pain due to failed previous endometriosis treatment and were undergoing surgical removal of 
endometriotic lesion tissue.  A total of 55 subjects were enrolled (N = 23 in the proliferative stage 
of the menstrual cycle, N = 32 in the secretory stage of the menstrual cycle and included women 
with stage I/II (N = 20) and stage III/IV (N = 35) endometriosis.  No subjects had taken GnRH 
analogs or hormonal therapy within 3 months prior to surgery.  A total of 55 endometrial biopsies 
(eutopic endometrium) and 77 matched (same patient) endometriotic lesions were collected.  All 
specimens were collected by the same surgeon (TF) at Cleveland Clinic or University of Kansas 
Medical Center (KS) with emphasis on minimizing sample contamination from 
underlying/surrounding non-endometriotic lesion tissue.  To do so, endometriotic lesions were 
excised and sent to pathology for confirmation of endometriosis, which was defined as the 
presence of endometrial glands and stroma. Tissue was excised using sharp scissors with no 
energy. During the excision the underlying tissue was separated from the lesion tissue.  A portion 
of the same sample lesion which was sent for endometriosis confirmation by a pathologist was 
utilized for research.  Research samples were immediately snap-frozen, stored at -80 ºC and then 
shipped to the University of Kansas Medical Center.  Stage of the menstrual cycle was determined 
from the patient’s medical records with day 1 defined as the onset of menses.   
Tissue samples used as non-endometriosis controls were obtained from the University of Kansas 
Medical Center Department of Pathology and Laboratory Medicine.  Endometrial tissue in the 
control groups consisted of women with uterine leiomyomas (N=12) or endometrial polyps (N=8) 
of which 10 samples were obtained during the proliferative stage of the menstrual cycle (N=10) 
and ten from the secretory (N=10) stage of the menstrual cycle.  Eutopic and matched ectopic 




proliferative (N=12; N=4 stage I/II and N=8 stage III/IV) and secretory (N=12; N=6 stage I/II and 
N=6 stage III/IV) stage of the menstrual cycle.   As no difference in RPLP1 mRNA, protein or 
miR-451 expression was noted among stages of the menstrual cycle or stages of endometriosis, 
data were collapsed and analyzed as ectopic versus eutopic tissue unless otherwise noted.   
Immunohistochemistry staining and histo-scoring 
 
The tissues were fixed with 10% neutral buffered formalin and subjected to immunohistochemical 
(IHC) localization using RPLP1 (Anti-RPLP1 antibody (Abcam 121190); dilution (1:300). IHC 
was performed following the recommendations of the manufacturer using VectaStain ABC system 
(Vector laboratories, Inc.).  Protein localization was identified as a positive reaction in dark brown 
coloring on the tissue slides.   
For H-Score assessment, the level of protein was quantitated in each cell type (epithelial, stroma, 
etc.) indicated as regions of interest (ROI).  We selected several sections as ROI within each 
endometrial biopsy and, due to the limited amount of tissue in endometriotic lesions compared to 
eutopic endometrial biopsies, we quantitated the entire lesion cross- section as the ROI.  The 
reaction product/signal intensity was then scored as 0 (absent), 1 (weak), 2 (moderate) or 3 (strong) 
and the percent of cells expressing these levels of intensity were calculated in each ROI.  The H-
SCORE was then obtained from this information (average level of intensity X percent of cells at 
that intensity) for semi-quantitative measurement of the positive staining. 
Statistical analysis   
To test the null hypothesis that the mean levels of RPLP1, miR-451a, and CCNE1 levels in ectopic 
endometriosis and eutopic endometriosis patients are the same, versus the alternative that the mean 




was used. For correlation studies of RPLP1 V1, V2, CCNE1, and miR-451a delta ct values in each 
lesion, Pearson’s correlation was used.  For comparison studies of the in vitro 12Z cells treatment 







1. MiR-451a regulates the expression of RPLP1 in 12Z immortalized endometriotic 
epithelium cell line. 
We previously reported that the net level of miR-451a expression was increased in 
endometriotic lesion tissue, but overall, lesion expression is heterogeneous. We also found that 
there was a correlation between miR-451a expression and cellular proliferation [130]. 
Our recently published data showed that miR-451a level is mis-expressed in human 
endometriotic lesion tissue, and its level is negatively correlated with cellular survival [159] . 
To examine the role of miR-451a in human endometriotic lesions, we used our cell model, 12Z 
immortalized endometriotic epithelial cell line. The cells were transfected with pre-mir-451a, 
or pre-NT-miR as a (non-targeting) control.  Total RNA and protein were extracted at 24h and 
48h post-transfection. We focused on 24-hour time point to confirm the detection of early 
protein changes in response to miR-451a transfection. The isolated proteins were used to run 
2-dimensional differential in- gel electrophoresis (2D-DIGE; performed by Applied Biomics, 
Hayward, CA) experiments to assess the differential protein profiles between transfection 
groups (Figure 5; this data is representative of 3 separate analysis of different cell transfection 
studies). Out of hundreds of expressed proteins; 60 proteins were shown to be differentially 
expressed between targeting and non-targeting cells. We selected twenty-five of these proteins 
for identification and further analysis for which the ratio changes of the protein differential 
expression (obtained from in-gel DeCyder software analysis) between pre-miR-451a and pre-
NT transfected cells in which protein expression was >1.5-fold.   Proteins were then isolated 










Figure 5. Proteomic analysis of endometriotic epithelial cells (12Z) by CyDye switch and 2-
dimensional fluorescence difference gel electrophoresis (2D-DIGE). 12Z cells were transfected 
with pre-miR-451a or pre-NT, protein was isolated and then labelled with Cy5 (red) and Cy3 
(green), respectively. Over-expressed proteins in pre-miR-451a transfected cells are shown in red, 
and over-expressed proteins in pre-NT transfected cells are shown in green. The most differentially 
expressed proteins were marked (circle and number). Out of 60 proteins marked in the gel, we 
identify a few proteins including protein number #57, which was identified as RPLP1(arrow). 



























2. MiR-451a inhibits RPLP1 transcript and protein expression: 
To confirm our initial finding in 2D gel analysis that RPLP1 is down-regulated by miR-451a, 
we examined RPLP1 mRNA and protein expression in 12Z cells transfected with either pre-
miR-451a or pre-NT (negative control).  Protein and RNA were isolated at 24h and 48h post-
transfection and qRT-PCR and Western analysis were performed (n=3). As displayed in Figure 
6A, RPLP1 mRNA level was significantly reduced in pre-miR-451a transfected cells 
compared to the negative control at 48 h post-transfection (P<0.05; N=3). In contrast, 
insignificant increase in the expression of RPLP1 was seen at 24h (P>0.05; N=3). To confirm 
our findings on the protein level, we examined the protein expression in the same set of cells 
by Western blot analysis. As depicted in Figure 6B, RPLP1 protein demonstrated a reduction 
at 48h post-transfection in 12Z cell transfected with pre-miR-451a compared to pre-NT 





Figure 6. miR-451a reduces the expression of RPLP1 mRNA and protein. Immortalized 
human endometriotic epithelial cell line (12Z) were transfected with miR-451a or pre-NT 
(negative control) 
(A) qRT-PCR analysis of RPLP1 expression in 12Z cells after transfection with pre-miR-451a 
or pre-NT. At 24 h post-transfection, RPLP1 transcript was insignificantly higher in 12Z 
cells transfected with pre-miR-451a compared to negative control (P>0.05; N=3). In 
contrast, the level of RPLP1 mRNA was significantly reduced 48 h post-transfection in 
miR-451a transfected cells compared to the pre-NT transfected cells (P<0.05; N=3). Data 
were normalized to the level of 18S transcript, and represented as the fold change from 
control (pre-NT) ± SEM.  Data were analyzed by one-way ANOVA followed by Bonferroni 
post-hoc analysis. 
(B) Western blot analysis of RPLP1 protein in 12Z cells transfected with either miR-451a or 



























































3. RPLP1 expression is increased in endometriotic lesions and it localizes to glandular 
epithelium: 
Based on the above in vitro observation that miR-451a may inhibit the expression of RPLP1 in our 
cell model, 12Z cell line, we hypothesized that miR-451a reduces lesion survival and growth in a 
pathway that involves RPLP1. 
To test this hypothesis, we first wanted to confirm and localize the expression of RPLP1 in human 
endometriotic lesion tissue. To do so, we conducted a preliminary assessment using a total of 60 
archived eutopic (N=10 secretory stage, N=10 proliferative stage) and matched ectopic 
(endometriosis) endometrial tissues from women with confirmed endometriosis (N=10 secretory 
stage, N=10 proliferative stage) as well as eutopic endometrium from women without 
endometriosis as a control (N=10 secretory stage, N=10 proliferative stage). Samples were 
obtained from the University of Kansas Medical Center, Department of Pathology and Laboratory 
Medicine, and classified as either proliferative or secretory stage of the menstrual cycle.  For this 
preliminary study, all women with endometriosis had stage I/II disease.  Samples were prepared 
for immuno-histochemical localization of RPLP1 as described in (“Materials and Methods”) 
section.  As depicted in Figure 7A-B, RPLP1 was localized primarily to the glandular epithelium 
(indicated by the arrows) and its expression (indicated by intense brown staining) was substantially 
elevated in the ectopic lesions of endometriosis women compared to matched eutopic tissues, and 
eutopic endometrium from women free of endometriosis. More importantly, RPLP1 expression in 
ectopic lesion from women in proliferative stage of the menstrual cycle (Figure 7A) was 
significantly higher compared to ectopic lesion from women in the secretary stage of the mensural 
cycle (Figure 7B).  To further assess the expression of RPLP1 in these tissues, we used the H-




positive staining. As displayed in figure 7C, the H-score of the ectopic tissues was higher than the 
matched eutopic and the eutopic control, and this elevation is more predominant in the proliferative 
phase of the menstrual cycle. All in all, these results agree with the observation that ectopic lesion 
tissues from the proliferative stage of the menstrual cycle are highly proliferative and this 







Figure 7. RPLP1 expression is elevated in human ectopic lesion tissue and localized in the 
glandular epithelium. Immunostaining for RPLP1 in ectopic endometriotic tissue and matched 
eutopic tissues from women with confirmed endometriosis, and eutopic control from women 
without endometriosis (A) in the proliferative stage of menstrual cycle (B) in the secretory stage 
of menstrual cycle.  The arrow illustrates the location of RPLP1 protein in glandular epithelium of 
the ectopic tissues (brown color indicates positive staining and was scored as 3 = strong, 2 = 
moderate, 1 = weak and 0 = absent). The intensity of the staining, which indicates the degree of 
expression, is elevated in the ectopic tissue from patients with endometriosis compared to matched 
eutopic and eutopic control, which show very light expression of RPLP1. All magnifications were 
X20 
(C)The immunohistochemical histological score (H-score) of RPLP1 in endometrial 
tissues (ectopic and eutopic) in both stages of menstrual cycle. H-score significantly 
increases in ectopic tissue from patient with endometriosis, and it is more elevated in 
proliferative stage compared to the secretory stage. (controls; N=30, P< .05). Data are 
presented as the mean + SEM and were analyzed by one-way ANOVA followed by 










































4. RPLP1 mRNA and protein is highly expressed in human ectopic endometriotic lesions 
and correlates with lesion proliferation 
To confirm the above finding that RPLP1 is highly expressed in human ectopic lesions, we utilized 
human tissues (eutopic endometrial tissue from women with endometriosis, N=55, and matched 
ectopic lesions, N=77) from the Cleveland Clinic, Department of Obstetrics and Gynecology. We 
first analyzed RPLP1 (variant 1 and variant 2) mRNA expression, by qRT-PCR, in matched 
eutopic and ectopic tissue from women with endometriosis. Stage of endometriosis (I/II versus 
III/IV) did not influence expression of RPLP1 so data were collapsed and analyzed as eutopic 
versus ectopic endometrial tissue. As depicted in figure 8A, the fold change of expression (ratio 
of lesion/eutopic) of RPLP1 V1 was greater (>1.0) in 67% (52/77) of ectopic endometriosis lesion 
tissue compared to matched eutopic endometrium, however, 32% (25/77) of the lesions expressed 
lower level of RPLP1 V1 (<1.0). Similar to this, the fold change of expression of RPLP1 V2 (figure 
8B) was greater (>1.0) in 54% (42/77) of ectopic endometriosis lesion tissue compared to matched 
eutopic endometrium and lower (<1.0) in 45% (35/77) of the lesions. 
The overall mean fold change of expression of both variants was significantly higher (3.72-fold 
increase; P<0.01) in ectopic lesion compared to eutopic tissues as shown in figure 8C. Since we 
have two variants of RPLP1, we correlated their expressions in the same lesions, which showed 
positive correlation as depicted in figure 8D (Pearson r = 0.8542; P<0.0001).  We next performed 
Western blot analysis to examine the expression of RPLP1 at the protein level in matched eutopic 
and ectopic tissue from women with endometriosis. As displayed in figure 8E, RPLP1 protein was 
greater in ectopic lesion tissues compared to matched eutopic endometrium.  Changes in protein 




miR-451a and RPLP1, we measured the total expression level of miR-451a in these lesions. As 
shown in figure 9A 57% (34/59) of the ectopic lesions expressed higher level (>1.0) of miR-451a, 
and 43% (25/59) express lower level (<1.0) compared with matched eutopic tissue. Furthermore, 
the correlation study performed demonstrated that miR-451a is negatively associated with RPLP1 
V1(Pearson r = - 0.32; P<0.001; N=73) in the same lesion as displayed in figure 9B.  This 
observation suggested to us that high levels of miR-451a were associated with lower levels of 
RPLP1 and might suggest an anti-proliferative role of miR-451a via modulation of RPLP1 
expression. 
To test the hypothesis that RPLP1 plays a role in inducing the survival and proliferation of 
endometriotic lesion tissue, we evaluated the expression of endometriotic lesion markers which 
we have previously demonstrated as indicators of lesion “survival status”; we assessed the cell 
proliferation marker (CCNE1) in the same tissues samples that were analyzed above. Figure 10A 
shows insignificant elevation of CCNE1 mRNA in ectopic lesion tissues compared to matched 
eutopic tissues (1.65-fold increase; P>0.05), consistent with the elevation of RPLP1 mRNA. This 
observation was confirmed by the correlative study illustrated in Figure 10B that demonstrated 
that RPLP1 expression is positively correlated with the proliferative marker CCNE1 (Pearson r = 
0.571; P<0.01; N=69). 
To this point, we interpret these data to suggest that the up-regulation of RPLP1 in endometriotic 





Figure 8. RPLP1 mRNA and protein are elevated in endometriotic lesions. Endometriotic 
lesions and matched eutopic tissue were utilized for RNA and protein isolations for RPLP1 and 
CCNE1. 
(A) qRT-PCR analysis of RPLP1 V1 in ectopic lesion shows fold change in expression 
(from highest to lowest) for RPLP1v1.  Note that 25/77 lesions expressed lower 
levels of RPLP1v1 (<1.0) compared to matched eutopic endometrium and 52/77 
lesions expressed higher levels of RPLP1v1(>1.0).  Please notice that RPLP1 
expression ranges from about 10-fold lower in some lesions to approximately 100-
fold higher in others compared to matched eutopic tissue. 
(Note that sample numbers 74 -77 were capped at a 9-fold increase in this figure; actual fold 



































Figure 8 (continued). RPLP1 mRNA and protein are elevated in endometriotic lesions. 
Endometriotic lesions and matched eutopic tissue were utilized for RNA and protein isolations for 
RPLP1 and CCNE1. 
(B) qRT-PCT analysis of RPLP1 V2 in ectopic lesion shows fold change in expression 
(from highest to lowest).  Note that 35/77 lesions expressed lower levels of RPLP1v2 
(<1.0) compared to matched eutopic endometrium and 42/77 lesions expressed higher 
levels of RPLP1v1(>1.0).   
(Note that sample numbers 75 -77 were capped at a 9-fold increase in this figure; actual fold 


























































Figure 8 (continued). RPLP1 mRNA and protein are elevated in endometriotic lesions. 
Endometriotic lesions and matched eutopic tissue were utilized for RNA and protein isolations for 
RPLP1 and CCNE1. 
(C) qRT-PCR analysis of RPLP1 (V1 and V2) expression in endometrial tissues 
demonstrates significant increase of the mean fold changes of both variants in the 
ectopic lesions compared to eutopic tissues higher. (3.72-fold increase; P<0.01) 
(D) Comparative analysis of the delta ct values of RPLP1 V1 and V2 in the same sample 
shows positive correlation of the expression of both variants. (Pearson r = 0.8542; 
P<0.0001) 
(E) Western blot analysis of RPLP1 protein shows elevation in the ectopic lesion 































































Figure 9. The expression of miR-451a transcript is heterogenous and negatively associated 
with the expression of RPLP1 V1 in endometriotic lesions. Endometriotic lesions and matched 
eutopic tissues were processed for RNA isolation and for the examination miR-451a transcript 
level. 
(A) qRT-PCR analysis of miR-451a which demonstrates the fold change of expression 
of miR-451a is differentially expressed among all lesions. Note that 34/59 shows 
higher level (>1.0) of miR-451a transcript compared to matched eutopic, and 25/59 
shows a reduction in ectopic lesions (<1.0). 
(B) Represented Delta ct values for miR-451a and RPLP1 V1 in the same sample.  
Lower delta ct values correspond to a higher level of mRNA expression. 
Endometriotic lesions which express high levels of miR-451a (lower left corner of 
graph) expressed low levels of RPLP1 V1, and the lesions which express lower 
levels of miR-451a mRNA (upper right corner of graph) express higher levels of 
RPLP1 V1 mRNA.  A Comprehensive analysis of 73 total lesions demonstrated a 
negative correlation between miR-451a and both variants of RPLP1. (Pearson r = - 

























































Figure 10. RPLP1 mRNA and protein are positively correlated with the expression with the 
proliferation marker, CCNE1. 
(A) qRT-PCR analysis of CCNE1 expression in endometrial tissues illustrates a non-
significant increase (1.65-fold increase; P>0.05) of the mean fold change in the 
ectopic lesions compared eutopic tissues. 
(B) Delta ct values for RPLP1v1 and CCNE1 in the same sample.  Lower delta ct values 
correspond to a higher level of mRNA expression. Endometriotic lesions which 
express high levels of RPLP1 (lower left corner of graph) also expressed high levels 
of CCNE1, while lesions which express lower levels of RPLP1v1 mRNA (upper 
right corner of graph) express lower levels of CCNE1 mRNA.  Overall assessment 
of 69 total lesions revealed a positive correlation between transcripts. (Pearson r = 
0.571; P<0.01; N=69). 
RPLP1, CCNE1 data were normalized to the level of 18S transcript, and 































































5. RPLP1 enhances cellular proliferation and survival in 12Z immortalized endometriotic 
epithelial cells 
Our data confirmed the up-regulation of RPLP1 transcript and protein levels in human 
endometriotic lesions, which might be controlled by miR-451a. Furthermore, we established that 
the expression of RPLP1 in human endometriotic lesions is positively correlated with the 
expression of CCNE1, a proliferative marker. RPLP1 was already identified as survival and 
proliferation promoter in tumors, accordingly, we wanted to determine if RPLP1 plays similar role 
in endometriosis by enhancing the growth and establishment of the endometriotic lesions. To test 
this hypothesis, 12Z cells were transfected with non-targeting (negative control) or siRNA to 
RPLP1 (n=3), which provided transient knockdown of RPLP1. Following this, RNA was collected 
at 24, 48, and 72 h post-transfection to assess the expression of cell proliferation marker cyclin E1 
(CCNE1), and tumor suppressor marker phosphatase and tensin homolog (PTEN). RPLP1 
knockdown was associated with a reduction in the proliferation marker (CCNE1) (Fig. 11 A) and 
an elevation of tumor suppressor marker (PTEN) (Fig. 11 B). To confirm RPLP1 knockdown, 
qRT-PCR (P<0.05; N=3) (Figure. 11 C) and protein analysis (Figure. 11D) were performed for 
RPLP1. This alteration in markers expression was not noticed in control 12Z cells transfected with 
non-targeting siRNA 
Since we found that 12Z cells express high levels of RPLP1, the transient transfection with siRNA, 
may not be optimal for long-term studies.  This postulation was supported by data displayed in 
figure 11C which shows that 12Z cells transfected with siRNA for RPLP1 re-expressed RPLP1 
transcript in 72 hours post-transfection. 
To address this concern, we developed stable RPLP1 deficient cell lines to be utilized in further 




containing a non-targeting cDNA or shRNA to RPLP1 (N=3) (Genecopoeia, Rockville, MD). To 
confirm the transduction, cells were cultured with puromycin (2 µg/ml) for 72h to select positively 
infected cells.  As displayed in Figure 12 A-B, endogenous depletion of RPLP1 resulted in cell 
death and a significant decrease in cell survival in the lenti-virus infected cells. collectively, these 

















Figure 11. RPLP1 Knockdown reduced cell survival and pro-apoptotic markers. 
Immortalized human endometriotic epithelial cell line (12Z) were transfected with siRNA for 
RPLP1, or non-targeting siRNA (negative control)., and represented as the fold change from 
control (non-targeting) ± SEM. RNA and protein were isolated from the cells at 24h, 48h, and 72h 
post-transfection to perfume qRT-PCR analysis for CCNE1 (A), PTEN (B), and RPLP1 



































































Figure 12.  Establishment of stable 12Z cell line with RPLP1 knockdown by lentiviral 
pseudoparticles resulted in reduction in cell survival. Endometriotic epithelial cells (12Z) was 
transfected with GFP- lentiviral pseudoparticles containing a non-targeting cDNA or shRNA for 
RPLP1, the cells were cultured and treated with puromycin after 48h for positive cells selection. 
The cells then were collected 72 h post transfection (n=3). 
(A) The viability of 12Z cells was determined by the exclusion of Trypan Blue. The 
number of viable 12Z cells transfected with ShRNA for RPLP1 was significantly 
reduced compared to the 12Z control (P<0.001). 
(B) Fluorescent microscopy of the 12Z cells demonstrated a decrease in the number of 
cells transfected with ShRNA for RPLP1 (green fluorescence) compared to the 12Z 
















































Discussion:   
Endometriosis is a disease characterized by the establishment, growth and survival of ectopic 
endometrial tissue (endometriotic lesion). miR-451a is already established as an oncogene in 
several tumors including breast, liver, and bladder cancer by suppressing the expression of genes 
responsible of cell growth, survival and angiogenesis [190-194] . Thus, it is not of a surprise that 
a similar role of miR-451a was also found in endometriosis. Endometriotic lesions share similar 
characteristics to tumors such as higher proliferative and growth rate, increase inflammation, 
estrogen responsiveness, and gene mutations [195-199].  
It should be noted that the expression of miR451a in endometriotic lesions is heterogeneous and 
was correlated with cellular proliferation [131, 159]. This finding was confirmed by a previous 
study in our laboratory that showed that the mean fold change of miR-451 (now referred to as miR-
451a) expression was significantly higher in ectopic lesions compared to eutopic tissues [159]. 
The elevation of miR-451a was negatively associated with the expression of CCNE1, a 
proliferation marker, and positively with PTEN, a proapoptotic marker [159, 200], which supports 
its role as tumor suppressor in endometriotic lesion tissue. The reason for the heterogenous 
expression may be due to the “proliferation status” of the lesion where newly formed lesions 
express low levels of miR-451a and high levels of CCNE1 and are thus more proliferative.  We 
postulate that as the lesions progress and eventually regress and become necrotic, miR-451a levels 
rise while CCNE1 levels decrease and the lesion eventually regresses.  This postulate is currently 
being explored in our laboratory. 
In this study, we wanted to gain additional insight into the mechanism by which miR-451a reduces 




epithelial cells showed downregulation of ribosomal protein, RPLP1, in 2-DiGE analysis which 
was confirmed in a separate series of 12Z cell transfections both at the mRNA and protein level.   
RPLP1 is a ribosomal protein that forms the ribosomal stalk in 60S subunit, and aids in translation 
[201]. In gynecological tumors, RPLP1 was found to be highly expressed and was correlated with 
cellular proliferation [179]. Overall, there are limited studies exploring the physiological role 
RPLP1 in disease development, however, those data that are available support the notion that 
RPLP1 is essential for cellular growth and proliferation. Based upon this, we hypothesized that 
RPLP1 expression is related to the establishment and survival of endometriotic ectopic lesions. 
This study is the first to identify the expression of RPLP1 in endometriotic lesion tissue and its 
potential regulation by miR-451a.  Our studies define yet another novel pathway which may 
contribute to the pathophysiology of endometriosis.  Future studies will explore the targeting of 
this pathway as a potential, non-hormonal therapy for endometriosis. 
To begin to explore the function of RPLP1, we first evaluated its level of expression in human 
samples. Immunohistochemistry staining showed higher expression of RPLP1 in the epithelial 
tissues taken from patients with endometriosis versus disease-free women, and this elevation was 
higher in the proliferative stage of menstrual cycle compared to secretory stage. As the 
proliferative stage is when the endometrium grows and thickens, the higher level of RPLP1 in the 
diseased tissues may accelerate the process. In further analysis, RPLP1 RNA and protein in the 
ectopic lesions were higher compared to matched eutopic tissue from the same patient. RPLP1 
RNA expression was higher (>1) in 67% (for RPLP1 V1) and 54% (for RPLP1 V2) in ectopic 
lesions versus paired eutopic tissues.  Further data that support the the notion that RPLP1 may be 




these lesions demonstrated a positive correlation with the expression of Cyclin E1 (CCNE1), a 
proliferative marker. 
Our data suggests that RPLP1 expression could be suppressed by miR-451a in endometriosis 
which causes increase in lesion proliferation. Thus, we used the same lesions examined for RPLP1 
to investigate the expression of miR-451a. We assumed that miR-451a will be lower in the ectopic 
lesions and this will explain the up-regulation of RPLP1. Contradictory to our assumption, miR-
451a mRNA showed higher expression in 57% (>1) of the lesions compared to matched eutopic 
tissues. Thus, we correlated the levels of miR-451a and RPLP1 in each lesion individually and 
found negative correlation, which confirms our hypothesis.  It should be noted that the differential 
expression of miR-451a and RPLP1 in these samples could be caused by the status of these lesions 
upon isolation. The heterogeneity of the endometriotic tissues is a hallmark of the disease, which 
creates difficulty in providing consistent data. Thus, the utilization of in vitro cell model, such as 
12Z cells, is highly preferred to overcome this issue in endometriosis research.  
In our cell model, 12Z cell line, the reduction of RPLP1 by siRNA demonstrated an up-regulating 
of PTEN, pro-apoptotic marker, and downregulating of CCNE1, proliferative marker, which 
indicated a reduction in proliferation and survival. The logic of using these markers for assessing 
cellular proliferation is the lack of evidence that either of these proteins are direct targets of miR-
451a. However, because of the transient transfection established by siRNA, the level of RPLP1 
started to increase at 72h post-transfection. Thus, we used GFP- lentiviral pseudoparticles 
containing shRNA to RPLP1 which caused a reduction in cell number.  
Overall, these data support previous studies that show the tumor suppressing effect of miR-451a 




proliferation (Figure 13).  In next chapter, we discussed a potential pathway that explains how 





Figure 13. The anti-proliferative effect of miR-451a is assumed to be partially through 






































miR-451a-c-Myc pathway regulation of 60S acidic ribosomal protein P1 
















Introduction: Endometriosis is a chronic inflammatory disease in women of reproductive age in 
which endometrial tissue establishes and survives in ectopic locations, yet the mechanisms that 
drive lesion survival are poorly understood. We have previously identified RPLP1 as a novel factor 
that modulates endometriotic epithelial cell survival. RPLP1 has been identified as a c-Myc 
responsive gene in rat fibroblasts (Guo et al., 2000), but a similar pathway has not been established 
in endometriotic lesion tissue/cells. The objective of the current study was to examine the role of 
c-Myc in regulating RPLP1 expression in endometriotic lesion tissue and epithelial cells to 
decipher the role of this protein in endometriosis pathophysiology. 
METHODS: c-Myc and RPLP1 mRNA was assessed using qRT-PCR in paired endometriotic 
lesion tissue and eutopic endometrium from women with endometriosis (N=77 lesions and N=55 
eutopic). RPLP1 regulation by c-Myc and cell survival were assessed in vitro using the 
endometriotic epithelial cell line, 12Z. 
RESULTS: Average expression level of lesion c-Myc mRNA was significantly greater compared 
to paired eutopic endometrium (4.1-fold increase; P<0.001). Lesion c-Myc mRNA levels were 
positively and significantly correlated with those of RPLP1 (Pearson r = 0.56; P<0.01). To evaluate 
if c-Myc modulated 12Z cell RPLP1 expression, 12Z cells were transfected with c-Myc siRNA 
and RPLP1 mRNA and protein expression were examined. Forced expression of c-Myc siRNA 
significantly suppressed c-Myc expression as well as that of RPLP1 (P<0.05; N=4). As miR-451a 
putatively regulates both c-Myc and RPLP1, we examined if it could modulate their expression. 




significantly reduced both c-Myc mRNA and protein expression as well as that of RPLP1 (P<0.01; 
N=4) which was associated with reduced cell survival. 
CONCLUSIONS: The average level of expression for both RPLP1 and c-Myc are significantly 
elevated in endometriotic lesion tissue and display a positive correlation. Further, c-Myc regulation 
of RPLP1 expression involves post-transcriptional regulation by miR-451a. Our observations 
continue to support our notion that miR-451a expression modulates endometriotic lesion survival 







MicroRNAs are small, non-coding, nucleotides sequences that control gene expression post-
transcriptionally [132]. The expression of miRNAs is essential for normal tissues and cellular 
development and may contribute to many pathological conditions such as cancer, auto-immune 
and inflammatory diseases [202-205]. The role of miRNAs in developing and maintaining ectopic 
lesions in endometriosis was investigated immensely [131, 155, 156, 159, 206]. 
 Endometriosis is a chronic inflammatory disease that affects women of reproductive age and 
contributes to a high morbidity rate [20, 29, 207]. It is characterized by the establishment of 
endometrial tissues in ectopic locations.  Several miRNAs were found to be mis-expressed in 
women with endometriosis including miR-451a, which is one of the most deregulated miRNAs in 
endometriotic lesions of patients with endometriosis [131, 152, 154, 159]. Recently, our group 
demonstrated that the level of miR-451a is negatively associated with endometriotic lesion and 
epithelial cell survival through potentially targeting RPLP1, Ribosomal Protein Large P1. 
 Although the essential function of RPLP1 in guiding protein translation is well-established, its 
role in disease development is still under investigation [208]. The available data suggest that 
RPLP1 contributes to cellular proliferation, transformation, and tumorigenesis [178, 179, 189]. In 
addition, Artero-Castro and colleges [179] demonstrated that expression of RPLP1 in 
gynecological tumors and autoimmune disease is elevated leading to increased cellular 
proliferation. It was also shown that RPLP proteins are elevated in the endometrial carcinoma that 
spread to the myometrium tissue [179]. Another study performed to investigate the function of 
RPLP1 in mammalian development proposed that RPLP1 is important to maintain proper cellular 




proliferation and induced apoptosis of progenitor cells. This was caused by a disturbance of key 
cell cycle and apoptosis regulators such as cyclin A, cyclin E, p21CIP1, p27KIP1, p53. Upon 
deletion of RPLP1 in fibroblasts, protein synthesis did not change, but the expression pattern of 
some proteins was affected, including proteins involved in protein folding and unfolding, 
apoptosis, and cell signaling [189].  
Our finding of RPLP1 elevation in endometriotic lesion tissue and its pro-survival role in 
endometriosis is the first to identify this novel protein as a player in endometriosis 
pathophysiology. Furthermore, the expression of RPLP1 was negatively associated with that of 
miR-451a. Thus, RPLP1 was predicted to be a potential target of miR-451a. In this study, we want 
to explore this regulation and identify additional mediators that are involved in the miR-451a-
RPLP1 pathway. This was achieved by using bioinformatic resources to determine if the miR-
451a seed sequence binds to the 3’UTR of RPLP1, the main mechanism that allows miRNA to 
repress gene expression. In addition, we performed a review of the available literature to uncover 





Materials and Methods 
Cell culture and transfection assay 
 
12Z immortalized endometriotic epithelia cells were obtained from Dr. Linda Griffith, MIT via a 
Materials Transfer Agreement (MTA).  The endometriotic 12Z cells were seeded at density of 1 × 
106 cells/ml of media in T-75 flask using complete culture media: phenol red-free Dulbecco's 
Minimum essential medium (DMEM)/Ham's F12 (Sigma Chemical Co.) + 10% charcoal stripped 
FBS (Atlanta Biologicals, Atlanta, GA, USA) + Pen-Strep (Sigma Chemical Co). Once the cells 
reached approximately 90% confluency, the cells were passed and plated into 6 wells plates at 1 × 
105 cells/ml in phenol red-free Dulbecco's Minimum essential medium (DMEM)/Ham's F12 
(Sigma Chemical Co.) with no FBS and P/S added and placed in the incubator for 24h. 
For miR-451a transfection, after 24h of plating the cell, 12Z cells were transfected using 
Lipofectamine 2000 transfection agent (Life Technologies/Ambion, Inc.) following the 
recommendations of the manufacturer with either Lipofectamine 2000 transfection reagent 
mixed with 30 nM of pre-miR451 (pre451; Life Technologies/Ambion, Inc., Grand Island, NY, 
USA) or a non-targeting mimic (NT-mimic, negative control; Life Technologies/Ambion, Inc.). 
At 24h and 48h post-transfection, RNA and proteins were collected for qRT-PCR, and western 
blot. 
For Myc knockdown, cells were transfected using Lipofectamine 2000 transfection agent (Life 
Technologies/Ambion, Inc.) following the recommendations of the manufacturer.  For this 
experiment, 12Z cells were plated at 1 × 105 of 6-well plates in DMEM: F12 with pen/strep and 
10% FBS for 24h. Cells were transfected with either Lipofectamine 2000 transfection reagent 




The transfection was performed at 24h, and 48h after plating to maximize the transfection 
efficiency. At 24h and 48h post-transfection, RNA and proteins were collected for qRT-PCR, and 
western blot. For each treatment, cells were cultured in duplicates and then for RNA and protein 
analysis.  
RNA isolation and qPCR 
For assessment of mRNA, total RNA was isolated using the Tri-reagent (Sigma Chemical Co., St. 
Louis, MO, USA). Then, the total RNA (1 µg in 20 µl) was used for reverse transcription using 
RT kits (Applied Biosystems; Foster City, CA, USA), according to the manufacture instructions. 
Primer-Blast was used for primers design, and for 18S (control). The primers used in this study 
are RPLP1 V1: forward 5’-TGACAGTCACGGAGGATAAGA-3’, reverse 5’- 
CCAGGCCAAAAAGGCTCAAC-3’. RPLP1 V2: forward 5’-CTCACTTCATCCGGCGACTA-
3’, reverse 5’-GCCAGGGCCGTGACTGT-3’. c-Myc: forward 5’-
GTAGTGGAAAACCAGCAGCC-3’, reverse 5’-AGAAATACGGCTGCACCGAG-3’ were 
synthesized by Integrated DNA Technology (IDT, Coralville, IA). The resulting samples were 
used for qRT-PCR by using QuantStudio 7 Flex System. All samples were run in triplicate, and 
the calculation was done by using the average values, and the 2-delta-delta CT method. In human 
tissues experiment analysis, human 18S primers probe reagents were analyzed, and the fold 
changes were normalized to the eutopic endometrium. In 12Z human endometriotic cells 
experiment analysis, human 18S primers probe reagents were analyzed, and the fold changes were 
normalized to the non-targeting (negative control). All Samples were tested in triplicates and 





Protein Isolation and Western blot 
 
The human tissues were homogenized in in RIPA Buffer (Cell Signaling Technology, 9806) with 
PMSF (Cell Signaling Technology, 8553S) and total protein concentration measured using Bio-
Rad by Protein Assays ([Catalog 3500-0006], Bio-Rad Laboratories, Richmond, CA, USA).  
To isolate the protein from the 12Z human endometriotic epithelial cell line, the protein was 
isolated by using lysis buffer (Cell Signaling Technology, 9803) with PMSF (Cell Signaling 
Technology, 8553S), and then the Bio-Rad Protein Assay ([Catalog 3500-0006], Bio-Rad 
Laboratories, Richmond, CA, USA) was used to determine the total protein.  
The same amount of protein (50 µg) was electrophoresed through 12% Bis (2-hydroxyethyl) 
amino-tris(hydroxymethyl)methane (w/v) gels and electro-blotted onto nitrocellulose membranes 
(Invitrogen). Primary antibodies: Myc (Protein Tech Cat# 10828-1-AP), RPLP1 (Protein Tech 
Cat# 216363-I-AP) and goat anti-rabbit secondary antibody (1:5000; GE Healthcare/Fisher 
Scientific, Pittsburgh, PA, USA) were used. To normalize the protein expression levels, stripping 
and re-probing for beta-actin (Abcam, Cambridge, MA, USA). The immuno-detection was 
performed by using enhanced chemiluminescence (ECL) kit (Thermo Scientific, Waltham, MA, 
USA). 
Human Tissues 
We utilized tissue samples from our IRB-approved bank of specimens which were obtained from 
the University of Kansas Medical Center, Department of Pathology and Laboratory Medicine 
and/or the Department of Obstetrics and Gynecology at the Cleveland Clinic.  This consists of 
paraffin-embedded tissue sections for immunohistochemistry studies as well as frozen tissue for 




Samples were obtained from subjects between the ages of 21 and 45 who presented with pelvic 
pain due to failed previous endometriosis treatment and were undergoing surgical removal of 
endometriotic lesion tissue.  A total of 55 subjects were enrolled (N = 23 in the proliferative stage 
of the menstrual cycle, N = 32 in the secretory stage of the menstrual cycle and included women 
with stage I/II (N = 20) and stage III/IV (N = 35) endometriosis.  No subjects had taken GnRH 
analogs or hormonal therapy within 3 months prior to surgery.  A total of 55 endometrial biopsies 
(eutopic endometrium) and 77 matched (same patient) endometriotic lesions were collected.  All 
specimens were collected by the same surgeon (TF) at Cleveland Clinic or University of Kansas 
Medical Center (KS) with emphasis on minimizing sample contamination from 
underlying/surrounding non-endometriotic lesion tissue.  To do so, endometriotic lesions were 
excised and sent to pathology for confirmation of endometriosis, which was defined as the 
presence of endometrial glands and stroma. Tissue was excised using sharp scissors with no 
energy. During the excision the underlying tissue was separated from the lesion tissue.  A portion 
of the same sample lesion which was sent for endometriosis confirmation by a pathologist was 
utilized for research.  Research samples were immediately snap-frozen, stored at -80 ºC and then 
shipped to the University of Kansas Medical Center.  Stage of the menstrual cycle was determined 
from the patient’s medical records with day 1 defined as the onset of menses.   
 Tissue samples used as non-endometriosis controls were obtained from the University of Kansas 
Medical Center Department of Pathology and Laboratory Medicine.  Endometrial tissue in the 
control groups consisted of women with uterine leiomyomas (N=12) or endometrial polyps (N=8) 
of which 10 samples were obtained during the proliferative stage of the menstrual cycle (N=10) 
and ten from the secretory (N=10) stage of the menstrual cycle.  Eutopic and matched ectopic 




proliferative (N=12; N=4 stage I/II and N=8 stage III/IV) and secretory (N=12; N=6 stage I/II and 
N=6 stage III/IV) stage of the menstrual cycle.   As no difference in RPLP1 mRNA, protein or 
miR-451 expression was noted among stages of the menstrual cycle or stages of endometriosis, 
data were collapsed and analyzed as ectopic versus eutopic tissue unless otherwise noted.   
Statistical analysis 
To test the null hypothesis that the mean levels of Myc level in ectopic endometriosis and eutopic 
endometriosis patients are the same, versus the alternative that the mean level in ectopic 
endometriosis patients is higher, a paired one-tailed t-test (0.05 significance level) was used. For 
correlation studies of Myc and RPLP1 V1 delta ct values in each lesion, Pearson’s correlation was 
used.  For comparison studies of the in vitro 12Z cells treatment groups, one-way ANOVA was 











1. The expression of RPLP1 is potentially regulated through a miR-451a-Myc 
pathway: 
The expression of RPLP1 was downregulated in 12Z cells with forced expression of miR-451a, 
however, based on the bio-informatic prediction tools; TargetScan 7.1, MicroRNA.org, and 
TargetRank, RPLP1 was not predicted to be a potential target of miR-451a, therefore, miR-
451a is not expected to bind to the 3’UTR of RPLP1. Thus, we did literature review in Pubmed 
using the following keywords: RPLP1, ribosomal protein large P, and ribosomal protein LP1. 
There are only a few papers published about the functionality of this protein outside of 
ribosomal protein synthesis. A paper published by Qingbin and colleges [200] examined 
differentially expressed genes between c-Myc null and c-Myc wildtype rat fibroblast cells 
using cDNA micro-array analysis, and found that RPLP1 is upregulated in response to c-Myc. 
Based on this finding, we did another literature review and bio-informatic analysis which 
revealed that Myc is a direct target of miR-451a which can bind to its 3’UTR (figure 14A). 
Therefore, we hypothesized that miR-451a directly targets Myc which reduces the expression 
of RPLP1 and causes reduction in cell survival. 
To test our hypothesis, we transfected 12Z endometriotic epithelial cells with 25 nM of pre-
miR451a and pre-NT (negative control), and the protein and RNA were collected at 24h and 
48h post-transfection to examine the level of Myc and RPLP1 by qRT-PCR and western blot, 
respectively. As displayed in Figure 14B, the expression level of Myc transcript was 
significantly lower at 24h and 48h post-transfection (P<0.001; N=4). Correspondingly, the 
expression of Myc protein was detected to be lower than the negative control at 48h post-




pattern of reduction (figure 6A-B). RPLP1 mRNA (P<0.05) and protein expression was 
significantly lower at 48h post-transfection, which confirmed the downregulation of miR-451a 


















Figure 14. Over-expression of miR-451a in 12Z endometriotic epithelial cell line reduced the 
expression of Myc mRNA and protein. 12Z cells were transfected with pre-miR-451a (25 nm) 
or Pre-NT (negative control), and RNA and protein were isolated at 24 and 48h post-transfection 
for RNA and protein analysis. 
(A) miR-451a binding sites to Myc 3’UTR was predicted by MIRANDA  
(B) qRT-PCR analysis of Myc mRNA demonstrated a reduction in the level of Myc 
transcript in 12Z cells transfected with pre-miR-451a compared to negative control 
cells, at 24h and 48h post-transfection (The expression of Myc was normalized to 
18S). (At 48h: P<0.001; N=4).  Data were analyzed by one-way ANOVA followed 
by post-hoc analysis using Bonferroni testing.  All data are displayed as the mean 
fold change from 24h NT + SEM (N=4).  
(C) Western blot of the cell lysates showed a downregulation of Myc protein in 12Z 
cell transfected with pre-miR-451a compared to non-targeting cells at 48h post-





















































2. Myc deletion reduced the expression of RPLP1 in 12Z endometriotic epithelial cell 
line: 
To confirm that the expression of RPLP1 is regulated by Myc, we knocked down the 
expression of Myc by transfecting 12Z cells with siRNA for Myc or non-targeting siRNA 
(negative control) at 24h and then did another transfection at 48h. The RNA and protein were 
collected at 24h and 48h following the double transfection to analyze the level of Myc and 
RPLP1 transcript and protein by qRT-PCR and western blot. As shown in figure 15A and 15C, 
the expression levels of Myc mRNA and protein were significantly reduced at 24h and 48h 
compared to the negative control (P<0.04; N=4), which confirms that the knockdown was 
successful.  This reduction was associated with the downregulation of RPLP1. As depicted in 
figure 15B, the expression level of RPLP1 transcript was dramatically reduced at 24h and 48h 
as a result of Myc deletion compared to the negative control (P =0.05; N=4). In addition, 
RPLP1 protein was shown to be reduced in 12Z cells transfected with siRNA for Myc at 24h 
and 48h post-transfection, compared to the non-targeting cells (Figure 15C). These findings 








Figure 15. Myc Knockdown reduced RPLP1 expression. Immortalized human endometriotic 
epithelial cell line (12Z) were transfected with siRNA for Myc, or non-targeting siRNA (negative 
control) at 24h and 48h, RNA and protein were isolated after each time points (n=4). The 
expression is represented as the fold change from control (non-targeting) ± SEM.  
(A) qRT-PCR analysis of Myc and RPLP1 variants (V1 and V2) expression (B) at 24h and 
48h post-transfection demonstrated a reduction following the transfection with siRNA for 
Myc.  Data were analyzed by one-way ANOVA followed by post-hoc analysis using 
Bonferroni testing.  All data are displayed as the mean fold change from 24h NT + SEM 
(N=4). 
(C) Western blot of Myc and RPLP1 of cell lysates, which showed downregulation in 12Z 













































3. Myc mRNA and protein is over-expressed in human endometriotic lesions and 
positively correlated with the expression of RPLP1: 
To confirm that Myc controls the expression RPLP1 in human endometriotic lesions, we first 
measured the level of Myc mRNA by qRT-PCR, in matched eutopic and ectopic tissue from 
women with endometriosis. For this analysis, we used human tissues (eutopic endometrial tissue 
from women with endometriosis, N=55, and matched ectopic lesions, N=77) from the Cleveland 
Clinic, Department of Obstetrics and Gynecology. Myc expression was not influenced by stage of 
menstrual cycle (proliferative versus secretory) or stage of endometriosis (I/II versus III/IV) so 
data were analyzed as eutopic versus ectopic endometrial tissue.  As displayed in figure 16A, the 
fold change of expression of Myc mRNA was higher (>1.0) in 70% (54/77) of the ectopic lesions 
compared to matched eutopic tissues. Further, 30% (23/77) of the ectopic lesions showed lower 
expression of Myc transcripts (<1.0) compared to matched eutopic tissues. The overall mean fold 
change of expression of Myc transcript was significantly higher in ectopic lesion compared to 
eutopic tissues (4.1-fold increase; P<0.001) as shown in figure 16B. The expression of RPLP1 and 
Myc transcripts was assessed and compared in the same sample, which shows that the level of 
expression of RPLP1 and Myc was positively correlated (Pearson r = 0.56; P<0.01) (figure 17A). 







Figure 16. Total expression of Myc transcripts is elevated in endometriotic lesions compared 
to matched eutopic tissues. 
(A) qRT-PCR analysis of Myc mRNA in endometriotic lesions showed an elevation of the 
fold change of expression of Myc (>1.0)  in 54 /77 (70%) and downregulation (<1.0) in 
23 / 77 (30%) of the endometriotic lesions compared to matched eutopic tissues. Data 
were analyzed by unpaired t-test and are displayed as the mean + SEM fold change 
from eutopic endometrium (N=55 eutopic endometrium, N=77 matched ectopic 
lesions). 
(Note that sample numbers 75 -77 were capped at a 15-fold increase in this figure; actual fold 
increases for samples 75, 76 and 77 were 23.27, 32.72, 52.45-fold higher, respectively.) 
(B) qRT-PCR analysis of Myc transcript in endometriotic lesions represented by the mean 
fold change of expression of Myc demonstrated to be increased in ectopic lesions 








































Figure 17. The expression of Myc is positively correlated with RPLP1 in human 
endometriotic lesions. 
(A) The data represented by Delta ct values for Myc and RPLP1 in the same sample.  
Lower delta ct values correspond to a higher level of mRNA expression. 
Endometriotic lesions which express high levels of Myc (lower left corner of graph) 
also expressed high levels of RPLP1, while lesions which express lower levels of 
Myc mRNA (upper right corner of graph) express lower levels of RPLPL1 mRNA.  
Overall assessment of 71 total lesions revealed a positive correlation between 
transcripts RPLP1 (Pearson r = 0.56; P<0.001). 
Myc and RPLP1 data were normalized to the level of 18S transcript, and 



















































































To expand our knowledge on the expression and role of miR-451a and RPLP1 in endometriosis 
pathophysiology, we wanted first to determine if RPLP1 is a direct target of miR-451a. For this 
purpose, we used target predictions resources including TargetScan 7.1, MicroRNA.org, and 
TargetRank. These tools suggested that RPLP1 is not a potential direct target of miR-451a. 
Therefore, we hypothesized that RPLP1 is a potential indirect target of miR-451a, through an 
alternative mechanism or pathway allowing miR-451a to control the expression of RPLP1. 
According to our data, it is tempting to classify endometriosis into ribosomopathies considering 
our finding of ribosomal protein dysregulation. However, it should be noted that RPLP1 and 
RPLP2 are located free in the cytoplasm and only form the ribosomal stalk to participate in protein 
translation [209]. Hence, RPLP1 may gains its function in driving cellular and lesion proliferation 
by interacting with other factors or proteins in its cytoplasmic free state, and not from its role in 
ribosomal structure. Supporting this hypothesis, a previous study conducted to investigate the 
effect of ribosomal proteins knockdown, including RPLP1, on ribosome function and structure 
which demonstrated that the number and function of ribosomes were not decreased upon RPLP1 
reduction and the total expression profiles were not compromised [180].  
There was limited available research focusing on the function of RPLP1 in pathological conditions; 
one study conducted by Guo and colleges found RPLP1 as a c-Myc responsive gene [200]. Myc 
(v-myc myelocytomatosis viral oncogene homolog) is a transcriptional factor that dimerizes with 
another protein, Max, and binds to the E-box sequence of the promoter sequence and controls the 
expression of downstream genes. It regulates the expression of 15% of genes in human [210] and 




mis-expression of Myc was defined as a “hallmark” of cancer [215] and it is detected in several 
types of cancer including breast [216], lung [217], ovarian cancer [218] and prostate cancer [219]. 
Furthermore, dysregulation of Myc was also identified in inflammatory and autoimmune diseases 
such as rheumatoid arthritis [220], and chronic liver disease, and found to stimulate the expression 
of inflammatory factors [221].  
In cancer cell lines, several studies showed that Myc is a direct target of miR-451a, and this was 
confirmed at the RNA and protein levels, as well as through the use of reporter assays [157, 160-
162]. In endometriosis, the expression of Myc was found to be highly expressed in the epithelial 
ectopic lesions compared to eutopic tissues and associated with proliferation [222]. In human 
endometriotic cyst stromal cells (ECSCs), c-Myc was found to be suppressed by miR-196b [223]. 
Further studies indicated the up-regulation of Myc in endometriotic lesions compared to eutopic 
endometrium from women with or without endometriosis [124, 182, 224-227]. However, most of 
these were descriptive studies to show the differential expressed proteins profile and have not 
investigated the proliferative mechanism of Myc in endometriotic lesions. Based on this, we 
hypothesized that miR-451a may directly bind to Myc, which controls the expression of RPLP1 
and modulates proliferation.  
The expression of c-Myc in the human samples was significantly elevated in ectopic lesions 
compared to eutopic tissues, and positively corelated with the expression of RPLP1. Furthermore, 
our in vitro study confirmed that c-Myc is a potential direct target in 12Z cell line, this is 
demonstrated by reduction of c-Myc RNA and protein levels as a result of miR-451a over-
expression. The knockdown of c-Myc caused a significant decrease in RPLP1 expression, which 




Based on our understanding of the endometriotic lesion pathophysiology, which is expected to go 
through cycles of regression and proliferation depending on hormonal and other unknown factors 
(figure 18), we propose that miR-451a may regulate lesion survival by directly repressing Myc, 
which in turn reduces the expression of RPLP1. Because of RPLP1’s role in proliferation, its 
downregulation leads to a reduction in cell survival and proliferation. On the other hand, low levels 
of miR451a in the lesion allows expression of Myc and, therefore, increases the expression of 


















































Matrix metalloproteinases and endometriosis:  Their Role in Disease 
pathophysiology and potential as therapeutic targets [228] 
 
This chapter is reprinted with permission. Z. Alali, K. Swan, W.B. Nothnick, Matrix 
Metalloproteinases and Endometriosis: Their ROle in Disease Pathophysiology and Potential as 





















Background: The matrix metalloproteinase (MMP) system is a group of enzymes, which 
function to modulate the tissue structure and degrade the extracellular matrix (ECM), a 
process required in cellular repair, proliferation, apoptosis, and angiogenesis. The role of 
MMPs in endometriosis pathophysiology has been examined, and it is hypothesized that 
mis-expression of MMPs in endometrial cells or surrounding tissues is a key factor in 
promoting the attachment, invasion, and angiogenesis required for establishment of ectopic 
lesions. Objective:  The objective of this review is to update the current state of knowledge 
on the role of MMPs in the pathophysiology of endometriosis and discuss the potential utility 
of treatments that may directly or indirectly target their action in endometriosis.  Results:  
In this review we summarize the current state of knowledge on the MMPs and the 
pathogenesis of endometriosis, discuss the role of the MMPs in endometriosis 
pathophysiology, summarize current treatments for endometriosis and discuss potential 
utility of inhibition of MMP action in endometriosis treatment.  Conclusion:  Based upon 
the current state of knowledge, therapeutic approaches targeting MMPs may be useful in 
mitigating the proliferation and the establishment of the lesions, but further patient-based 






     Endometriosis is estrogen-dependent disease which is defined as the presence of ectopic 
endometrial tissue primarily within the pelvic cavity.  Endometriosis is characterized primarily by 
pelvic pain, and infertility. The factors which lead to the initial development, progression and 
survival of these ectopic lesions are poorly understood.  Matrix metalloproteinases (MMPs) are 
zinc-dependent endopeptidases that are involved in several biological functions including, tissue 
repair and remodeling. Normally, MMPs play a role in modulating the extracellular matrix and 
tissue remodeling which occurs within the endometrial lining during the menstrual cycle.  MMP 
expression and activity is proposed to be altered in endometriotic lesion tissue as a result of 
dysfunctional steroid and cytokine expression and/or action.  In turn, altered MMP 
expression/activity is proposed to enhance the invasion, attachment and proliferation of the ectopic 
lesion. In this review, we will highlight the potential role of the MMP system in the pathogenesis 
of endometriosis with emphasis on recent therapy targeting MMPs and their biological activity.   
2.  The Matrix Metalloproteinase System 
    The matrix metalloproteinase (MMP) system is a group of enzymes (the MMPs) and their 
enzyme tissue inhibitory regulators, the tissue inhibitors of metalloproteinases (TIMPs), which 
plays a role in numerous biological functions associated with extracellular matrix turnover and 
tissue repair. The major function of MMP enzymes is to degrade extracellular matrix proteins 
leading to tissue remodeling and repair, apoptosis, angiogenesis, cellular proliferation and 
invasion. MMPs are zinc-containing endopeptidases, which share the same structural domains; the 
pro-peptide, the catalytic domain, hinge region, and haemopexin-like C-terminal domain. 
Currently, there are 26 MMPs found, which have been classified according to their cellular 




     MMPs classes include, collagenase (MMP-1, MMP-8, MMP-13, and MMP-18), gelatinase 
(MMP-2, and MMP-9), stromeylsins (MMP-3, MMP-10, MMP-11, and MMP-27), matrilysins 
(MMP-7, and MMP-26), membrane type MT-MMP (MMP-14, MMP-15, MMP-16, MMP-17, 
MMP-24, and MMP-25), enamelysin (MMP-20), macrophage metalloelastase ( MMP-12), and 
other enzymes ( MMP-19, MMP-21, MMP-22, MMP-23A, MMP-23 B, MMP-28, and MMP-29).  
MMPs are mostly secreted proteins with exception of the membrane type, MT-MMPs, which 
anchor to the cell membrane. Normally, these enzymes are regulated in three stages, the first stage 
requires the transcription of these proteins, while the second stage involves the conversion of 
MMPs from the inactive zymogens form to the active form under the action of other proteases. 
Lastly, the MMPs are controlled at the tissue level by the TIMPs and the ratio of MMPs to the 
TIMPs must be tightly controlled [230]. 
     MMPs are released by many cells’ types, including endothelial cells, fibroblasts, and immune 
cells such as macrophages and neutrophils, and involve the regulation of various physiological 
processes. For example, the reproductive system is subjected to various structural changes in 
tissues architecture during the processes of ovulation, menstruation, and embryo implantation. 
MMPs have been investigated thoroughly as a significant player in these events. For instance, 
MMPs are postulated to enhance the ovulation process by breaking down the collagen components 
of the ovarian follicles, leading to its rupture and oocyte release [231].  Within the uterus, MMP-
7 mRNA has been associated with the endometrial epithelial cells in menstruation and tissue repair 
[232, 233] 
     The regulation of the activity of MMPs is essential to avoid disturbances in the normal balance 
in their levels, which could result in several pathological manifestations. MMPs are expected to 




factor (TNF-α).  Specifically, TNF-α is produced by macrophages due to injury or stress. TNF-α 
can bind to the membrane receptors on the targeted cell and stimulate the expression of MMPs. As 
a consequence, imbalance in the expression levels of MMPs, TIMPs, or regulatory factors is 
associated with some types of cancer and inflammation. For instance, increases the level of TNF-
α in peritoneal cavity of women is consider a promoting factor to increase the MMPs leading to 
endometriosis, a gynecological inflammatory disease [234]. 
3.  The Pathophysiology of Endometriosis 
     Endometriosis is an estrogen dependent disease characterized by the accumulation of 
endometrial stroma and glandular tissues ectopically, mostly on ovaries, fallopian tubes, and 
peritoneal lining of the pelvic cavity. The disease is primarily associated with pelvic pain, 
dysmenorrhea, and infertility. It affects around 10 % of women in reproductive age, with annual 
medical care cost of approximately $ 20 billion in United States [235]. Several theories have been 
postulated which propose mechanisms, origins and pathogenesis of endometriosis. The coelomic 
metaplasia theory suggests that the ectopic endometrial tissue is transformed from peritoneal 
mesothelium. The transformation of the tissues is explained to be enhanced by steroidal , and 
immunological stimuli [236]. A more recent theory was based on the observation that self-renewal 
adult stem cells/progenitors are located within the endometrium, which suggests a potential 
differentiation of these stem cells into endometrial cells and migration ectopically [237].  
     To explain the observation of endometriosis in female embryos, it is proposed that the 
endometrial cells outside of the uterus is generated originally from imperfect growth of Wolffian 




lesion is developed as a result of the existence of Wolffian or Mullerian ducts cells remnants which 
progress into estrogen-responsive lesion [110]. 
Retrograde menstruation is another theory which suggests that retrogradely shed endometrial 
fragments migrate through the fallopian tubes and attach to pelvic cavity organ surfaces 
establishing vascularization and eliciting estrogen responsiveness [235, 238, 239]. Although the 
theories explain the existence of endometrial cells in the ectopic locations, the rationales for the 
ability of these tissues to survive, invade, and avoid the immune response is still indefinite. 
Accordingly, endometriosis is also hypothesized to be a chronic inflammatory disorder caused by 
dysfunction or imbalance in the immunity components. 
     Supporting this hypothesis is the observation that women with endometriosis show high levels 
of activated macrophages and low natural killer cells [240]. A variety of cytokines have been 
shown to be highly expressed in the peritoneal fluid of women with endometriosis, giving more 
evidence of the inflammatory nature of the disease [241]. TNF-α, in particular, is a pro-
inflammatory cytokine which is elevated in the peritoneal fluid and sera of women with 
endometriosis and it is positively associated with the severity of the disease [242-244]. In addition, 
it is suggested that TNF-α polymorphism is a possible cause for the pathogenesis of endometriosis 
[245, 246]. TNF-α is proposed to enhance the proliferation of the endometriotic lesion while 
elevated level of peritoneal fluid TNF-α is proposed to introduce a toxic environment that reduces 
oocyte quality resulting in fertilization or implantation difficulties [247, 248]. The mechanism of 
action of TNF-α in endometriosis is postulated to be through stimulating the secretion of numerous 
components including MMPs, which help to degrade the extracellular matrix allowing the invasion 




4.  The Role of The MMP System in The Pathophysiology Of Endometriosis 
     In healthy women, the expression of MMPs fluctuates in a menstrual cycle-dependent fashion.  
MMP expression is elevated during the period of menstruation to regulate the degradation and 
shedding of endometrium, and in proliferate phase to guide the repairing process which occurs 
during regeneration of the endometrial lining. However, the expression of MMPs is more tightly 
controlled during the secretory stage of the menstrual cycle, particularly during the window of 
implantation [250]. In endometriosis patients, it has been found that the expression level of specific 
MMPs is higher in ectopic endometriotic tissues lesions compared to eutopic lesion suggesting a 
potential role of MMPs in stimulating the onset and the establishment of the disease. To date, 
studies have shown the elevation or mis-expression of MMPs and TIMPs in endometriosis 
patients, such as MMP-1[251, 252], MMP-2[253], MMP-3[254, 255], MMP-7[256, 257], MMP-
9 [258], MMP-13 [259], MMP14 (MT1-MMP) [253], MMP-24 (MT5-MMP) [260], TIMP-
2[252], and TIMP-3 [258]  (Table 1). 
      Due to the heterogenicity nature of the endometriotic tissues, and depending on the 
sample/biopsy under investigation; levels of MMPs and their inhibitors (TIMPs)  
Table 1.  Differential expression levels of matrix metalloproteinases (MMPs) and their 
tissue inhibitors (TIMPs) in human endometrium/endometriotic lesion tissue. 
 
MMPs/TIMPs    Study findings [reference] 





MMP-1 protein is elevated and TIMP-1 and-2 proteins are reduced in 







MMP-2 and MT1-MMP are up-regulated, and TIMP-2 is downregulated in 
eutopic endometrium from patients with endometriosis compared to 
endometrium from endometriosis-free women [26]. 
MMP-3 
 
MP-3 mRNA is elevated in peripheral blood of endometriosis patients 
compared to patients without endometriosis [28]. 
MMP-7 MMP-7 is differentially expressed in endometriosis depending on the types 
of endometriotic lesions [30]. 
MMP-9 
TIMP-3 
TIMP-3 is reduced in eutopic endometrium and ectopic endometriotic 
tissue compared to endometrium of women without endometriosis.  MMP-
9 and MMP-9/TIMP-3 ratio is elevated in ectopic tissues compared to 
endometrium from women with and endometriosis [31].   
MMP-9 
TIMP-1 
MMP-9 transcript is increased in eutopic endometrium of endometriosis 
patients compared to endometrium of control women.  
TIMP-1 transcript is decreased in ectopic lesion compared to eutopic 
endometrium of patients with endometriosis and control women [34]. 
MMP-9 MMP-9 is elevated in the plasma and peritoneal fluid in endometriosis 





The abundance of active MMP-13 and MT1-MMP / MMP-14 are reduced 
in peritoneal fluid of endometriosis patients compared to women without 
endometriosis [32]. 
MT5-MMP MT5-MMP level is increased in eutopic endometrium and ectopic 
peritoneal lesions of women with endometriosis [33]. 
 
could vary. For instance, TIMP-1 transcript was lower in human ectopic endometriotic lesion 
compared to matched eutopic endometrium and to endometrium from women without 
endometriosis [261]. On the contrary, recent proteomic studies to examine the protein profile of 




significantly higher in cervical mucus of patients with endometriosis compared to endometriosis-
free women [262]. 
      Evaluating the factors involved in activation or inhibition of MMPs is important to understand 
how MMPs contribute to the pathogenesis of endometriosis. A study was conducted to examine 
the level of MMP-9 in the serum, ascites, and endometriotic lesions in patients with confirmed 
endometriosis compared to control group. In this study the severity of the disease (endometriosis 
lesion staging), and the phase of menstrual cycle were documented. Elevated levels of MMP-9 
were detected in the serum and ascites of endometriosis patients compared to disease-free group. 
In the endometriosis patients group, it was found that MMP-9 is higher in ectopic endometriotic 
lesions compared to the eutopic endometrium, and that this elevation was more prominent in the 
proliferative stage and in the advanced stage of the disease than in subjects with less invasive 
stages [263, 264].  These results were interpreted to suggest a possible correlation between the 
severity of the disease and the pattern of MMP expression. Further, a prior study demonstrated a 
positive correlation between an increased ratio of MMP-9 to TIMP-1 with endometriosis 
pathogenesis [265].  
      Angiogenesis is an essential step in establishing and maintaining the ectopic lesion. To 
examine the factors controlling this process in endometriosis, Jana and colleagues examined the 
effect of MMP-2 and COX-2 inhibition on angiogenesis of the endometriotic lesion using an 
experimental mouse model for endometriosis. They found that there was a reduction in numbers 
of lesions formed in mice treated with inhibitors compared to the control mice. In vitro, the study 
showed decrease cellular migration and tubal development due to MMP-2 inhibition which 




invasiveness and angiogenesis of the disease has shown to be regulated through COX-2–PGE2-
pAKT pathway. [266]. 
        It is well-established that endometriosis is an estrogen-dependent and progesterone-resistant 
disease. In vitro, endometriotic cells show increased proliferation and growth following estrogen 
treatment, and lesion regression after progesterone supplement. These cyclic changes in 
endometrial tissues coincide with the expression level of MMPs which increases during the 
proliferative phase of the cycle and decrease during the secretory phase. Accordingly, the effects 
of estradiol treatment on the expression and the activity of MMPs have been investigated in several 
studies. Immunohistochemical analysis comparing the expression of MMP-1, ER-β, and ER-α in 
human endometriotic specimen to matched samples of endometrial tissues from the same patients, 
and to endometrium from healthy controls demonstrated a correlation in the expression of ER-β 
and MMP-1 in the ectopic lesion, in which both of these were elevated.  However, ER-α expression 
levels were reduced in the same tissues. This comparative analysis proposes potential involvement 
of MMP-1 in inducing endometriosis through an estrogen dependent pathway [267].  
       An in vivo study to investigate the role of steroid hormones in the MMPs expression was 
conducted by Wang and colleagues in which endometriosis was induced in immunocompromised 
mice using human endometrial tissue.  Mice were treated with estrogen, progestin, estrogen and 
progestin, and saline. The isolated lesion from estrogen and estrogen plus progestin groups showed 
high expression of MMP-2 and low TIMP-2.  In addition, TIMP-2 was lower in the progestin 
treated group. The authors concluded from this study that the cyclic hormonal changes increased 




     MMPs have also been examined based upon the inflammatory nature of endometriosis and its 
association with immune dysfunction and imbalance. It was found that the peritoneal cavity of 
endometriosis patients contains excessive level of TNF-α which stimulates the production of 
MMPs and the adhesion and attachment of the ectopic lesions.  Furthermore, TNF-α acts to 
increase the expression of other cytokines that further stimulate lesion establishment and survival.  
For example, TNF-α is postulated to elevate the synthesis of macrophage migration inhibitory 
factor (MIF), which is highly expressed in eutopic tissues,  and the active ectopic lesion of 
endometriosis patients and is involved in promoting the survival and establishment of the disease 
[269, 270].  The role of MIF in the pathogenesis of endometriosis was examined in a study using 
immunocompromised mice harboring human endometrial tissue derived lesion treated with the 
MIF antagonist, ISO-1.  Lesions isolated from ISO-1-treated mice displayed decreased levels of 
MMP-2 and MMP-9 which was associated with a decrease in lesion size, invasiveness, and 
survival [271]. This result suggested that MMPs may stimulate the migration and the severity of 
the disease through the same pathway as MIF. In addition, this study supports the hypothesis that 
endometriosis may be caused by a disturbance in the anti-inflammatory components leading to 
lesions escape from the host immune response.  Collectively, these data have indicated strong 
association of MMPs and the pathogenesis of endometriosis either through estrogen mediated 
mechanisms as well as inflammatory pathways.  
6.  Potential Targets in Developing New Treatments for Endometriosis 
6.1 Current treatments for endometriosis 
     Endometriosis treatment depends on the fact that endometriosis is a hormonal-dependent 
disease. Consequently, most of the available medications aim to inhibit the production or the action 




analogues. Alternatively, in severe stage of endometriosis when the available treatments fail to 
improve patient conditions, laparoscopic surgery is performed to remove the ectopic lesions. 
However, the surgical intervention is not the best approach for all patients especially for patients 
who have severe widespread endometriosis, because it may result in partial or complete 
hysterectomy to eradicate the disease. Controlling endometriosis through medications brings more 
hope for patients to improve quality of life and continue their reproductive life [44, 45].  
     Due to low cost and availability, combination of estrogen/progestin contraceptives and 
progestogens are used as the primary treatment options for endometriosis patients. These 
hormones, such as medroxyprogesterone (DMPA) and ethinyl estradiol, act in inhibiting ovarian 
function and subsequently in alleviating the pain associated with endometriosis [46-48]. However, 
there are considerable undesirable side effects including preventing pregnancy, depression, nausea, 
and weight gain, which make contraceptives  less-favorable for some patients [49]   
     Similarly, Dienogest (19-nortestosterone derivative) is progestin oral contraceptive that is used 
for endometriosis treatment. Dienogest has high affinity to PR (progesterone receptor), reduces 
the level of estrogen, and acts as antiandrogenic. In addition, Dienogest reduced the inflammation 
and the proliferation of endometriotic cells [50, 51]. Because of these features, the side effects 
associated with Dienogest administration are considerably lower than other available medications 
[52].  
     After all the surgical and medical treatments are exhausted, aromatase inhibitor (AI) is another 
treatment option that is suggested to be used. Aromatase is an enzyme that stimulates the 
conversion of steroidal precursors to estrogen. Therefore, inhibiting aromatase activity by AI 




associated pain [53]. Administration of this medication alone is linked to adverse effects. To limit 
these risks, it is recommended to use AI in a cocktail regime with other hormonal therapy such as 
OCPs or GnRH analogues for endometriosis treatment [54, 55]. 
     Gonadotropin - releasing hormone (GnRH) analogs, which block the release of gonadotropins 
hormones and ovarian estrogen production, are a common treatment for endometriosis. The 
reduction in estrogen level limits the growth and the survival of the ectopic lesion and suppresses 
the disease-associated symptoms. Yet, the hypo-estrogenic state introduced by GnRHa initiates 
some side effects such as reduced bone density, hot flashes, sweating, psychological disturbances; 
anxiety and depression. These associated outcomes arise because estrogen is necessary in various 
physiological processes other than uterine development. As a result, “add-back” therapy is 
followed to avoid these symptoms; a recent comparative study show that administration of GnRHa 
together with estradiol valerate and norethisterone acetate can mitigate the unfavorable effects and 
decrease the bone loss [56]. 
    Interestingly, there is indirect evidence that the above common treatments for endometriosis 
may elicit their beneficial effects by acting upon cytokines and possibly MMP action.  For 
example, GnRHa is expected to lessen the circulating peritoneal cytokines, possibly through 
estrogen reduction mechanisms [272]. It was also found that treatment of endometriosis patients 
with ultra-long GnRHa before IVF reduced the TNF-α cytokine in the follicular fluid, which lead 
to higher implantation and pregnancy rate [273]. Lastly, another study revealed that GnRHa may 
mediate a significant regression in the inflammatory nature of the peritoneal microenvironment in 
women with endometriosis [274]. These observations may suggest that it might be more efficient 
to target the ectopic implants by focusing on the inflammatory nature of the disease and aim to 




Finding a cure for endometriosis is important not only to control the common symptoms of the 
disease, but also to improve the quality of life of endometriosis patients. Few studies have linked 
endometriosis with the onset of depression and anxiety [32]. This may be attributed to the chronic 
pain associated with the disease. A study conducted to compare the psychological stress and 
depression in three groups: endometriosis patients with pain, pain-free patients, and control group 
with no endometriosis. The study showed that the quality of life and the psychological conditions 
were compromised in   patients who have endometriosis-associated with pelvic pain compared to 
the other two groups [33]. The anxiety and depression in endometriosis patients was not corelated 
with the stage of the lesion nor the age of the patients [34]. In addition, it is hypothesized that the 
mental disturbance in endometriosis patients may increase the intensity of the pelvic pain 
associated with endometriosis, which in turn increases the psychological stress [35]. Taken 
together these findings, it might be plausible to treat endometriosis with no or little hormonal 
interventions. These options, such as OCP, have already been proved to cause depression thta may 
exacerbate the psychological discomforts which endometriosis patients endure.  
6.2 The use of anti-MMP therapies for endometriosis treatment 
     As mentioned above, introducing a hypo-estrogenic state appears to be universal in treating 
endometriosis, even with the undesirable side effects. Considering alternative approach through 
inhibiting MMPs may carry potential in reducing the complications associated with current 
medications used. Based on current data, several MMPs are highly expressed in ectopic lesion 
which positively correlated with lesion remodeling, angiogenesis, invasiveness, and establishment. 
The inhibition of MMPs by TIMPs has been used successfully in research setting which resulted 
in reducing the lesions survival by altering the ratio of MMPs to TIMPs [275]. Other than using 




curcuma longa, could increase the expression of TIMP-2 which in turns confines the activity of 
MMP-2 leading to less invasive lesions and hinders disease development [276]. 
     Considering the hypothesis of endometriosis inflammatory origin, it is tempting to use anti-
inflammatory agents to manage the burden of the disease.  Treatment of mice with experimental 
endometriosis with lipoxin A4, an endogenous anti-inflammatory acid, showed decreased in the 
in the invasiveness and the size of the ectopic implants through the reduction of MMP-2 and MMP-
9 expression [277]. Similarly, using inhibitor for NF-kB (nuclear factor-kB) was suggested method 
to treat endometriosis. NF-Kb is transcriptional factor that is expected to be over-activated in 
endometriotic cells, through TNF-α cytokine. Upon activation, NF-Kb controls the production of 
specific genes, including MMPs which enhance the angiogenesis and the invasion of the lesion 
tissues. Accordingly, pyrrolidine dithiocaramate (PDTC)  was used to inhibit the action of NF-Kb, 
which results in downregulation of MMPs , reduction in the invasiveness of the ectopic lesion, and 
promoting apoptosis of endometriotic ectopic stromal cells [278].  Although limited in numbers, 
these studies suggest that MMP inhibitors may be beneficial but human studies clearly need to be 
conducted.    
6.3 Blocking MMP action with anti-tumor necrosis factor-α therapies  
     TNF-α is a pro-inflammatory cytokine which has been considered as a significant player in the 
development of endometriosis. The peritoneal levels of TNF-α is elevated imposing a potential 
role in increasing the invasion of the retrograded endometrial cells [123, 244, 279, 280]. This is 
expected to occur due to its positive effect on MMPs levels leading to increased expression of 
MMPs in ectopic lesion. Therefore, blocking the action of TNF-α would be useful to target MMPs 
which could be a potential, non-hormonal- therapy to treat the disease. Anti- TNF-α has been used 




of endometriosis, the use of Recombinant human TNF receptor: Fc fusion protein, (rh) TNFR: Fc, 
has been shown to limit the aggressiveness of the disease. Barrier and coworkers demonstrated 
that using etanercept, an anti-TNF-α antibody, subcutaneously in baboon model was effective in 
reducing the size and number of active red endometriotic lesions [281]. Similarly, a rat model of 
endometriosis was treated with etanercept and showed decreases in the size of implants compared 
to the control group [282].   More recently, the use of (rh) TNFR: Fc in vitro decreased the 
proliferation and adhesion of human endometrial stromal cells and decreased the levels of MMP-
1. Similar results using rhTNFR:Fc  were observed in vivo, using the mouse model of 
endometriosis where a reduction in the ectopic endometriotic lesion size was noted [283]. 
Unfortunately, the more recent use of rhTNFR:Fc as not been evaluated in humans, but the 
published data in animal models are promising and may support the use of anti- TNF-α as 
prospective therapy to treat and manage endometriosis.  
7.  Summary and Perspective 
     The pathophysiology of endometriosis is complicated and not well clear, which makes the 
process of finding a cure a hurdle task. Therefore, it may be rational if we consider endometriosis 
as a multi-factorial disease where a combination of factors, hormonal and immune factors, is 
involved to promote the attachment, aggressiveness and the angiogenesis of the ectopic lesion. The 
observation of the estrogenic stimulatory effects on the tissues drove the field to use the GnRHa 
as a major therapy to suppress the lesion growth and to control the disease; however, considering 
the patient’s quality of life and the associated complications, this may not be the ideal treatment. 
On the other hand, the dysregulation of the immunity and inflammatory components is well 
established. MMP, which is regulated by cytokines, has been linked to enhance the survival and 




limiting the adhesion of the tissue even with continuous steroidal stimulation which may reduce 



























Endometriosis is defined as presence of glandular and stromal tissue in ectopic locations, primarily 
within the pelvic cavity.  The process of lesion development initiates during menstruation which 
involves shedding of the endometrium that lines the uterus, followed by migration through the 
fallopian tubes, ectopic attachment/adhesion of retrogradely shed endometrial fragments, 
proliferation, and survival of the lesion. In this dissertation, we were interested in studying the 
modulators that induce the proliferation and survival of endometriotic lesion/endometriotic cells. 
Because of the important established role of miRNAs in endometriosis, we focused on detecting 
new targets of miR-451a to expand its pathway. The results of this study are expected to provide 
better understanding of the pathogenesis of the disease and identify potential therapeutic targets 
for endometriosis treatment.  
1- Over-expression of miR-451a reduced the level of RPLP1. 
In endometriosis, it is already established that miR-451a reduces cellular proliferation/survival by 
directly binding to and reducing the expression of genes including YWHAZ and MIF (Macrophage 
Inhibitory Factor) [131, 159]. Initially, we wanted to identify additional targets of miR-451a which 
may be relevant to the pathophysiology of endometriosis.   As miR-451a is predominantly, if not 
exclusively, expressed by endometrial/endometriotic glandular epithelial cells [131] we utilized 
the endometriotic epithelial cell line, 12Z as our experiment model.    We transfected 12Z cells 
with pre-miR-451a to integrate miR-451a protein targets using 2D gel analysis.  From the dozens 
of proteins which were differentially expressed, we narrowed our focus to 25 proteins that were 
differentially expressed using the criteria previously described [284].  For this project, we selected 
RPLP1 (Ribosomal protein Large P1) as our protein of interest based upon its role as a potential 
mediator of cell proliferation/survival and the facts that the protein has not be described in the 




RPLP1 in endometriosis is un-investigated, the available literature showed that RPLP1 is a 
constituent of ribosomal structure [170-173], further studies demonstrated elevation of RPLP1 in 
gynecological tumor [179], and it promotes cellular transformation and proliferation [178]. Thus, 
we hypothesized that RPLP1 plays a role in the proliferation of endometriotic lesions. Therefore, 
the focus of our study was to define the expression of RPLP1 in human endometriotic lesion and 
eutopic endometrial samples, study its function and regulation. 
2- RPLP1 protein is elevated in endometriotic lesions: 
The objective of this experiment was to examine the expression of RPLP1 in human endometriotic 
lesion and eutopic endometrium. RPLP1 transcript and protein was significantly higher in human 
endometriotic ectopic lesions compared to matched eutopic tissues from the same patient and 
compared to endometrium from women without endometriosis. Knowing that 
proliferation/survival are characteristics of endometriotic lesions, and considering the proliferative 
function of RPLP1, the elevation of RPLP1 in these specimens was logical and supports our 
working hypothesis. We also found positive association between RPLP1 and CCNE1 (Cyclin E1), 
a marker of proliferation, in the same lesion, which again supports our hypothesis.  However, it 
should be emphasized that although net RPLP1 expression in lesion tissue was significantly 
elevated compared to eutopic endometrium, there was a great deal of heterogeneity among the 
levels of expression within individual lesions.  It is well established that endometriotic lesion tissue 
are a heterogeneous tissue and this may be one reason that may hinder or delay the development 
of diagnostic/therapeutic targets.  We believe the level of expression of RPLP1 by individual lesion 
tissue plays a physiologic/pathophysiologic role and is not due to different cell populations that 
make up individual lesions.  We base this statement on the fact that we have evaluated the potential 




each cell type and found no significant differences [159] suggesting that differences in RPLP1 
expression could not be attributed to an enrichment or reduction in the proportion of epithelial cell 
content compared with eutopic tissue. 
This information leads us to believe that RPLP1 (and miR-451a) levels change as individual 
endometriotic lesions “age”.  While it is impossible to evaluate this in humans, the use of animal 
models such as the baboon or rodent, would allow for such evaluation by inducing experimental 
endometriosis and then evaluate lesion content at different time points.  
3- RPLP1 expression is essential to cell proliferation in cell model: 
To confirm the role of RPLP1 in cell model, we knocked down the expression of RPLP1 in 12Z 
cells and found reduction in the level of CCNE1 (proliferating marker), and elevation of PTEN 
(Pro-apoptotic marker) of cells lacking RPLP1. Transient knockdown of RPLP1 showed 
reduction in the number of viable cells and cell survival. The results of this study support our 
initial hypothesis and agrees with previous studies which suggest that RPLP1 is important in 
cellular proliferation and cell survival. 
In future, it would be interesting to see if RPLP1 inhibition causes also reduction in the number of 
ribosomes, which therefore triggering arrest in the global translation machinery and leads to cell 
death. If no significant change is detected in the number of ribosomes, it is interesting to examine 
the effect of RPLP1 knockdown in the translation of certain proteins necessary for cellular growth 
and survival. To confirm if RPLP1 has a central function in cellular proliferation, further studies 
could be developed to rescue RPLP1-depleted cells with RPLP1-ORF cDNA lentiviral particles, 





4- miR-451a regulates the expression of c-Myc in 12Z cells:  
At this point, we have already confirmed that forced expression of miR-451a causes a reduction 
of RPLP1 in 12Z cells. However, the process of miR-451a binding to the mRNA sequence of 
RPLP1 (3’ UTR, 5’ UTR, or other regions), which is essential for direct regulation of miRNAs, 
has not yet been confirmed. We looked at the bio-informatic resources available and found no 
evidence of such regulation. Therefore, we speculated that miR-451a controls the expression of 
RPLP1 indirectly, thus, we searched for up-stream regulators of RPLP1. While there are limited 
studies focusing on RPLP1 pathway, microarray-based study showed that RPLP1 is c-Myc 
responsive gene in rat fibroblast [200]. Interestingly, based on bio-informatic tools and previous 
studies, c-Myc, a universal transcription factor, is a direct target miR-451a [157, 158, 161]. 
Although this study was obtained from fibroblast cells (equivalent to the stromal cells in 
endometrium), the collective data was encouraging to suggest that miR-451a directly binds to c-
Myc and this regulates the expression of RPLP1.  Our findings showed that over-expression of 
miR-451a reduces Myc RNA and protein levels in 12Z cells. In addition, we demonstrated that 
Myc knockdown causes reduction in RPLP1 level, which validated that Myc is a potential 
regulator of RPLP1.  
In the future, we want to confirm that miR-451a is a direct repressor of c-Myc and indirect 
regulator of RPLP1. This can be performed by luciferase reporter assay to determine if miRNA 
binds to the 3’UTR of target gene. In addition, since c-Myc is a transcription factor that binds to 
the promoter sequence of its target gene to control its expression, the use of chromatin 
immunoprecipitation (ChIP) assay is useful to examine if c-Myc binds to the RPLP1 promoter 




it is important to note that RPLP1 may also be regulated by other intermediate proteins and/or 
other miRNAs, and not exclusively relying on Myc and miR-451a. 
Moreover, it would be interesting to see if any of the other candidate proteins identified in the 
2D-gel analysis are of Myc responsive genes.  
5- Identification of potential therapeutic targets of endometriosis: 
Because the main objective of expanding this pathway is to find new therapeutic targets for 
endometriosis; the need for further set of experiments in vitro and in vivo (using mouse, or 
baboon model for endometriosis) are required to find additional modulators in this pathway that 
are more specific to endometriosis. While RPLP1 is a novel finding in endometriosis 
pathophysiology, it may not be ideal to use RPLP1 inhibitor, if available, as method to reduce 
lesion development and treat the disease. Since RPLP1 is widely expressed in all cells and its 
expression is essential for ribosomal function and cellular survival, inhibiting its production/or 
function could be detrimental.  
Similarly, there are several Myc inhibitors that are used in research settings to investigate the 
effect of myc suppression [1]. Yet, there are limitations in using these inhibitors in humans due 
to their toxic effects.  Just recently, the FDA resumed the clinical trial on using Myc inhibitors 
such as APTO-253 to treat acute myeloid leukemia (AML) patients and high-risk 
myelodysplastic syndromes (MDS) [285]. In addition to the safety concerns regarding such 
inhibitors, the new medication should overcome the disadvantages of the current hormonal 
therapy of endometriosis such as depression, bone loss, and pregnancy prevention [56]. 




ovarian hormonal regulation. Overall, the use of RPLP1 or Myc inhibitors could be promising if 
specific targeting of endometriotic lesions is feasible. 
Further studies to expand the pathway of miR-451a may aid in treatment development. For 
example, miR-451a is potential repressor of matrix metalloproteinases (MMP-9 and MMP-2) in 
cancer [286, 287].  If such regulation occurs in endometriosis is yet to be defined. However, the 
expression of MMPs in endometriosis is well-established and discussed in depth in chapter 4 of 
this dissertation. The function of MMPs and their inhibitors (TIMPs) is to degrade the 
extracellular matrix and modify tissue structure in a controlled fashion [229]. The use of MMP 
biological inhibitors (TIMPS) was investigated in animal model of endometriosis and resulted 
in significant reduction of the size of endometriotic lesions [275], suggesting that such an 
approach may be feasible. 
In conclusion, our findings indicate that proliferation of endometriotic lesions is potentially 
promoted by a RPLP1-dependant pathway. In these lesions, the low level of miR-451a induces 
the expression of its target gene, c-Myc, and that in turn up-regulates the expression of RPLP1, 
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